Annual Report *2025*



Contents

3 Profile
3 Basic details
4 Editorial
5 Management
5 Organisational structure
6 Advisory bodies – Director's Advisory Board
7 Ethics Committee
7 Committee on Ethical Issues, Commercialisation Council
7 Scientific Council
8 Science and research
9 Preclinical Research Programme (VP1)
12 Clinical Research Programme (VP2)
14 Public Mental Health Research Programme (VP3)
17 Sleep and Chronobiology Research Centre (C1)
19 Psychedelic Research Centre (C2)
21 Research Centre for First Episodes of Severe Mental Illness (C3)
24 Virtual Reality Research Centre in Mental Health and Neuroscience (C4)
26 Centre for Sexual Health and Interventions (C5)
29 Centre for Advanced Studies of the Brain and Consciousness (C6)
32 Centre for Perinatal Mental Health (C7)
33 Projects undertaken in 2025
44 Funding providers and project numbers in 2025
45 Contract research 2025
47 Science and research outputs
55 Public engagement 2025
57 Clinical care
58 Organisational structure
59 Inpatient care, day hospitals, outpatient and referred care
60 Health insurers' shares of total reimbursements in 2025
61 Finance and human resources
63 Assets and liabilities: balances and movements
64 Balance sheet 2025
70 Income statement 2025
73 NUDZ pre-tax financial results
73 Institutional and grant funding over the last five years (CZK thousand)
74 NUDZ financial performance in detail, before tax
74 Cost comparison for 2024 and 2025 – principal activities
75 Revenue comparison for 2024 and 2025 – principal activities
75 NUDZ financial results 2020–2025 (CZK)
76 Selected total costs in 2024 and 2025
76 Approved budget for 2026 (CZK)
77 Financial comparison 2024 and 2025 – total costs
77 Financial comparison 2024 and 2025 – total revenue
78 Employees and collaborators (as at 31 December 2025)
79 Employee appointments and departures
79 Employees by age and gender (as at 31 December 2025)
80 Employees by education (as at 31 December 2025)
80 Payroll costs over the last five years
81 Personnel costs (incl. contributions, CZK)
81 Average salary (CZK, excl. other personnel payments)



Basic details

National Institute of Mental Health
(NUDZ)
Topolová 748, 250 67 Klecany

Phone: +420 283 088 111
E-mail: sekretariat@nudz.cz,
podatelna@nudz.cz
Website: www.nudz.cz
Data box: uehpcbb

Organisation ID: 00023752
Tax ID: CZ00023752
Bank details
Account: 25234081/0710
Czech National Bank, Prague branch
Na Příkopě 864/28, 115 03 Praha 1
SIC/SWIFT: CNBACZPP
IBAN: CZ3607100000000025234081

Profile

The National Institute of Mental Health (NUDZ) is a modern institution combining research and clinical practice. It serves as a centre for basic, experimental and applied research into the neurobiological and psychosocial mechanisms underlying the onset and course of the most severe mental disorders, and develops and tests new diagnostic and treatment methods. It also provides analyses and expert advice to public authorities, particularly on the organisation of mental health care and the ongoing reform of psychiatric care, while contributing to the development of the field and public understanding of it. The institute's clinical division provides standard and highly specialised inpatient and outpatient psychiatric care. As the Department of Psychiatry and Medical Psychology of Charles University's Third Faculty of Medicine, it delivers undergraduate and postgraduate education in psychiatry, psychology and neuroscience. Directly overseen by the Czech Ministry of Health, the institute was established on 1 January 2015 through the transformation of the Prague Psychiatric Centre. Its premises were built under the OP VaVpI project (CZ.1.05/2.1.00/03.0078), with total funding of CZK 971,000,000: CZK 825,350,000 from the European Regional Development Fund and CZK 145,650,000 from the Czech state budget.

Editorial

Dear colleagues, friends and partners,
With respect and pride in the entire team at the National Institute of Mental Health, I look back on 2025 — a year of systematic work, patient efforts to connect science with clinical practice, and responsible service to the public and the professional community.

Our research teams continued to advance knowledge in psychiatry, psychology and neuroscience, with a focus on translating their findings into everyday care — whether through innovations in diagnosis and treatment, stronger prevention programmes, or high-quality education for professionals across disciplines. Supporting the tools that underpin the mental health care system remained an essential part of our work: standards, methodologies and data infrastructures that facilitate informed decision-making at every level of care.

In 2025, we further strengthened the Institute's role as an expert guarantor and active contributor to the National Mental Health Action Plan. We contributed to the analytical and methodological groundwork for key measures, helped evaluate their impact, and provided expertise to interministerial working groups tasked with translating psychiatric care reform in the Czech Republic from strategy into everyday practice. The Action Plan is more than a document — it is a process, and the Institute's role within it extends beyond the boundaries of a single institution: we are a place where society's commitment to change meets scientific evidence and clinical experience. At a time when Czech psychiatry is in the midst of a demanding reform process, we see our role as a responsibility that we take seriously.

The past year was also one of consolidation and further development of our institutional capacity. Drawing on lessons from the challenging situations of previous years, we continued to refine procedures for providing timely, coordinated and sensitive support to people affected by events with consequences for mental health — with an emphasis on respect for individual dignity and shared responsibility across government departments, academia and civil society. At the same time, we remained mindful of those who provide care. Supporting our employees' mental well-being, ensuring a high-quality working environment and managing our operations efficiently are not peripheral concerns; they are essential to sustaining the Institute's excellence.

Today, the Institute is a place where science, clinical expertise and public service come together. In 2025, we continued to fulfil this threefold mission: we published scientific papers in international peer-reviewed journals, secured prestigious competitive grants from Czech and European funding bodies, contributed to the development of clinical practice guidelines, and trained tens and hundreds of professionals from across the country. Equally important was our role in raising public awareness and reducing the stigma surrounding mental health — through open, informed dialogue with the public, schools, patient and carer organisations, and the media. We believe that combining excellent research, accessible and high-quality care, and clear public communication offers the most reliable path towards a more resilient and better-informed society.

The annual report you are now opening is a record of what we have achieved together. It also represents a commitment for the year ahead. I thank all the Institute's employees for their professionalism, humanity and daily dedication, which give this work its true meaning. I thank our founding authority — the Ministry of Health of the Czech Republic — for its institutional support and trust. Special thanks go to our longstanding academic partner, the Third Faculty of Medicine at Charles University, whose collaboration connects research with the undergraduate and postgraduate education of a new generation of specialists in psychiatry and neuroscience, and which is an indispensable part of our shared academic mission. And I thank our extensive network of partners at home and abroad for their cooperation, without which much of what we present here would not have been possible.

With best wishes,

Professor Jiří Horáček, MD, PhD, FCMA
Director of the National Institute of Mental Health



Management



prof. MUDr. Jiří Horáček, Ph.D., FCMA

Director



MUDr. Tomáš Novák, Ph.D.

Deputy Director for Education



prof. MUDr. Pavel Mohr, Ph.D.

Deputy Director for Clinical Research



Ing. Lenka Menoušková

Deputy Director for Economic and Operational Affairs

Organisational structure



Advisory bodies – Director's Advisory Board

prof. MUDr. Jiří Horáček, Ph.D., FCMA
Director

prof. MUDr. Pavel Mohr, Ph.D.
Deputy Director for Clinical Care

MUDr. Tomáš Novák, Ph.D.
Deputy Director for Science and Education

Ing. Lenka Menoušková
Deputy Director for Economic and Operational Affairs

MUDr. Martin Brunovský, Ph.D.
Head of Research Programme

Mgr. Karolína Kuchaříková, Ph.D.
Head of Research Programme

RNDr. Karel Valeš, Ph.D.
Head of Research Programme

Petra Hlachová, M.A.
Head of Human Resources

Ing. Petr Nevole
Head of Building Management

Ing. Petra Holeňová
Head of the Project Office

Mgr. et Mgr. Iveta Fajnerová, Ph.D.
Head of Research Centre

Mgr. Kateřina Klapilová, Ph.D.
Head of Research Centre

PhDr. Jana Kopřivová, Ph.D.
Head of Research Centre

MUDr. Tomáš Páleníček, Ph.D.
Head of Research Centre

Ing. Daniel Rovný
Head of IT

MUDr. Antonín Šebela, Ph.D.
Head of Research Centre

MUDr. Filip Španiel, Ph.D.
Head of Research Centre

PhDr. et Mgr. Štěpánka Heřmánková, MBA
Healthcare Quality Manager

Mgr. Hana Macková
Chief Nurse

RNDr. Karel Valeš, Ph.D.
Chair of the Basic Trade Union Organisation

Ing. Jan Hubený
Chair of the Independent Trade Union Organisation

Ing. Martina Zavadilová
Fundraiser

Mgr. et Mgr. Alice Dolanská
Methodologist

Mgr. Lenka Sitná
Legal Adviser

Nikola Zwrtková
Head of Communications

Committee on Ethical Issues

Mgr. Veronika Kubáčová Langová
Committee Chair, Researcher

Commercialisation Council

RNDr. Karel Valeš, Ph.D.
National Institute of Mental Health
Executive of the Commercialisation Council

Ethics Committee

doc. MUDr. Martin Bareš, Ph.D.
Chair – NUDZ, Psychiatrist

Scientific Council

prof. Martin Alda, MD, FRCPC
Chair of the Scientific Council

Science and research



MUDr. Tomáš Novák, Ph.D.
Deputy Director for Research and Education


In 2025, in line with its mission, the research division continued its basic and applied research into the neurobiological and psychosocial mechanisms affecting mental health. These activities cover prevention, diagnosis, treatment and the wider societal impact of mental illness, and help introduce new services that improve quality of life for patients and the general population.

During the year, we worked on 61 nationally funded research projects, acting as the principal recipient in 36 cases (59%). Funding providers supported 19 projects through AZV, 14 through GAČR, 6 through TAČR, 5 through the Ministry of Labour and Social Affairs, 1 through the Ministry of the Interior and 7 through the Ministry of Education, Youth and Sports (including 4 under OP JAK). A further 9 projects received funding from other sources. We also participated in 17 projects involving international partners, mainly under Horizon Europe. Our research outputs consistently maintain outstanding quality: in 2025, half were published in Q1 journals, and we also achieved a high rating in the comprehensive evaluation of research organisations under Methodology 17+. The institute thus continues to strengthen its position in mental health and neuroscience research, both regionally and, in many respects, internationally.

However, 2025 will be remembered in the history of NUDZ above all for two major events.

In April, Professor Cyril Höschl, founder and first director of NUDZ, passed away. His influence and broad interests extended far beyond neuroscience and psychiatry, and he was also a great supporter and communicator of our research. We remember him with deep respect.

In September, prof. MUDr. Jiří Horáček, Ph.D., FCMA became the third director of NUDZ. A co-founder of the institute and its first Deputy Director for Science and Research, he is also a prominent figure in Czech psychiatry. He succeeded PhDr. Petr Winkler, Ph.D., who had significantly shaped the institute and its research over four years in office before resigning during the year. I thank Petr Winkler for his work and contribution to the institute, and wish Professor Horáček every success in fulfilling the vision and expectations he brings.



Preclinical Research Programme (VP1)

Head: **Alena Moudrá (until 10/2025), Karel Valeš (from 10/2025)**

Profile: In 2025, the Preclinical Research Programme focused on strengthening translational and application-oriented research at the preclinical level. It connected experimental and clinically oriented research to better understand the neurobiological mechanisms of severe neuropsychiatric, neurodevelopmental and neurodegenerative disorders, while developing methods for new diagnostic and therapeutic approaches.

The programme relied primarily on animal models, bioanalytical chemistry, molecular biology, cellular models, imaging methods, advanced nanomaterial characterisation and computational approaches. It emphasised close links between preclinical models and clinical questions in contemporary biological psychiatry and neuroscience, including the development of biomarkers, new pharmacological interventions and neuromodulation technologies.

Activities in 2025

Preclinical models of schizophrenia and translational biomarkers

The team continued developing animal and translational models of schizophrenia. A key result was the experimental validation of a double-hit model combining early postnatal immune activation with repeated pharmacological exposure during key developmental periods. The model revealed changes in social behaviour during adolescence without major disruption of sensorimotor function or general locomotion. These findings support its further use to study mechanisms linking early immune challenges, episodes resembling psychotic relapse and social dysfunction.


Neurodegenerative diseases and proteomic approaches

The programme contributed to a human post-mortem proteomic study of the effects of memantine in Alzheimer's disease. The study showed that memantine treatment is associated with subtle, biologically significant changes in the hippocampal proteome, particularly in mitochondrial proteins, synaptic signalling, and glutamatergic and GABAergic pathways.

Nanomedicine, molecular imaging and the MERIT project

The MERIT project continued developing and characterising MgO nanoparticles. Synthesis parameters were optimised, a range of physicochemical analyses were performed, including UV-Vis, DLS, TG-DTA, FTIR, XRD, NTA, XPS/EDS, SEM and TEM, and neurotoxicity assessment in neuronal cell lines was initiated. The work also included computational docking analyses of MgO and dendrimer–MgO against proteins associated with hypothalamic insulin resistance, initial design of IKK-beta-specific aptamers with the University of Tennessee, and the start of MRI database automation for future machine-learning algorithms with the Czech Technical University in Prague.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Preclinical Research Programme (VP1)

Non-invasive neuromodulation and cellular models

Experimental work and data analysis on the effects of low-intensity focused ultrasound (FUS) on calcium signalling in neuronal cultures were completed. The study used live-cell calcium imaging and quantitative fluorescence analysis to assess the safety and neuromodulatory potential of FUS at the cellular level.

Psychopharmacology, psychedelics and new drug development


In 2025, preclinical studies examining the safety and efficacy of psychedelic and psychopharmacological interventions were expanded. A published study of psilocybin demonstrated a narrow therapeutic window for antidepressant-relevant effects and emphasised the importance of precise dosing in future clinical translation. The programme also developed medicinal chemistry and preclinical evaluation of new candidate compounds, including a newly awarded AZV project on potential treatments for schizophrenia and alcohol dependence, and candidate selection for in vivo testing linked to a postdoctoral GAČR project.

Key results in 2025

The year 2025 brought several findings directly linked to the programme's translational mission. In schizophrenia modelling, a new double-hit model focused on social behaviour was published. In Alzheimer's disease research, the programme contributed to proteomic characterisation of the effects of memantine in the human hippocampus. In nanomedicine, the MERIT project progressed from material synthesis and optimisation to detailed characterisation and initial assessment of biological safety. Significant progress was also made in cellular models of focused ultrasound and in preclinical evaluation of psychedelics and new pharmacological candidates.

- HAKENOVÁ, K., MIKULECKÁ, A., HOLUBOVÁ, K., CHVOJKOVÁ, M., ŠLAMBEROVÁ, R., JURČOVIČOVÁ, J., ČECHOVÁ, B., PONIŠT, S., HORÁČEK, J., VALEŠ, K. A new two-hit animal model for schizophrenia research: Consequences on social behavior. IBRO Neuroscience Reports. 2025, 19, s. 38-49. DOI: 10.1016/j.ibneur.2025.05.012.
- FABRIK, I., KUPČÍK, R., FABRIKOVÁ, D., CHVOJKOVÁ, M., HOLUBOVÁ, K., HAKENOVÁ, K., HORÁK, M., SOUKUP, J., MANETHOVÁ, M., RUSINA, R., MATĚJ, R., RYSKA, A., SOUKUP, O. Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients. Proteomics. 2025, 25, s. 42-49. DOI: 10.1002/pmic.70006.
- BANO, I., JEEVANANDAM, J., TSENOV, G. Effects of focused ultrasound stimulation on various in vitro neurological cell models. Journal of Neuroscience Methods. 2025, 423, Article Number 110544. DOI: 10.1016/j.jneumeth.2025.110544.


NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Preclinical Research Programme (VP1)

- SEILLIER, L., ČECHOVÁ, B., SEILLIER, A., ŠLAMBEROVÁ, R. Psilocybin has a narrow therapeutic window as an antidepressant treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025, 138, Article Number 111368. DOI: 10.1016/j.pnpbp.2025.111368.
- JEEVANANDAM, J., TSENOV, G., DANQUAH, M. K., RUIZ-MOLENA, D., BOUSSIOS, S., OVSEPIAN, S. V. Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence. Molecular Diagnosis & Therapy. 2025/2026, 30(1), s. 19-46. DOI: 10.1007/s40291-025-00813-6.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Clinical Research Programme (VP2)

Head: **Martin Brunovský**


Profile: Clinically oriented research into the neurobiological basis of mood, anxiety, psychotic and cognitive disorders. To clarify the nature of mental disorders and target diagnostic and treatment approaches more precisely, the programme integrates clinical data with findings from neuropsychological, electrophysiological, neurostimulation and brain-imaging examinations.

Activities in 2025

In 2025, VP2 continued its clinical and translational research into neuropsychiatric disorders, focusing on identifying biological predictors of treatment response, individualising therapeutic approaches and linking clinical data with electrophysiological, neuropsychological, neurostimulation and neuroimaging methods.

A substantial part of the programme involved the Electrophysiological Therapeutic Predictors Working Group, which developed research into EEG markers of the effects of ketamine and antidepressant treatment in depressive disorders. Analyses examined changes in EEG signal complexity after a subanaesthetic dose of ketamine, the use of EEG vigilance to stratify patients with depression, and prediction of antidepressant response using graph theory and brain-connectivity analysis. This work strengthens the programme's translational focus on personalised psychiatry, using electrophysiological data both to describe pathophysiology and to select and optimise treatment. Research also covered the combination of tDCS with mirror therapy, assessment of motor function and physiological neglect, cognitive interventions, and the preparation and analysis of EEG data in depression and other clinical conditions. A significant translational output was a study of the therapeutic potential of acetyl-DL-leucine and N-acetyl-L-leucine in posterior fossa syndrome, linking neuropharmacological, neurorehabilitation and mechanistic aspects of this rare but clinically serious postoperative complication.

In non-invasive brain stimulation, the NIBS Working Group continued the AZV project NW25-04-00023 MASCOD, focusing on deep rTMS for OCD. Recruitment targets were exceeded in the first year, with more than 40 patients enrolled and comprehensive clinical, MRI and EEG data obtained for most of them. Preliminary results suggest a clinically relevant difference between active and sham stimulation, supporting further development of personalised stimulation interventions for OCD. Building on the OP JAK-funded Brain Dynamics / BRADY project, individualised modelling of the H-coil's electric-field distribution using SimNIBS was further developed with the Institute of Computer Science of the Czech Academy of Sciences. Preliminary data indicate that electric-field intensity in the right supracallosal ACC predicts clinical improvement, supporting individualisation of stimulation parameters.



Clinical Research Programme (VP2)


The methodological component of the programme focused on improving the accuracy and validity of electrophysiological measurements. In auditory steady-state response research, a significant artefact arising during sound stimulation was identified and characterised, and a prevention procedure was proposed. Further work integrated EEG and fMRI signals and developed advanced analytical approaches for processing multimodal data. Translational research was also expanded to characterise EEG microstates in rats and link behavioural and electrical activity in animal models relevant to the study of neuropsychiatric disorders.

In psychological research, the working group continued a grant-funded project on loneliness. Pre-publication work on "Akce Asanace" was also completed, and a book on this subject was published in 2025. Other publications addressed transgenerational transfer of trauma, the adaptation of Ukrainian women, changes in depression rates in recent years, and several smaller topics, including personality functioning and personality disorders.

Key results in 2025

- VLČEK, P., HORÁČEK, J., GRÜNEROVÁ-LIPPERTOVÁ, M., BRUNOVSKÝ, M. Therapeutic potential of acetyl-DL-leucine and its L-enantiomer in posterior fossa syndrome: Mechanistic insights. Drug Discovery Today. 2025, 30(6), Article Number 104389. ISSN 1359-6446. DOI: 10.1016/j.drudis.2025.104389.
- WENG-LAM, Ch., OLBRICH, S., JIANG, X., ZHANG, H., IP, Ch., BRUNOVSKÝ, M. Subanesthetic ketamine alters EEG signal complexity: Implications for treatment stratification in depression. Journal of Affective Disorders. 2025, 386, Article Number 119477, 1–10. ISSN 0165-0327. DOI: 10.1016/j.jad.2025.119477.
- BEČEV, O., LASKOV, O., BAKŠTEIN, E., ŠTROBL, J., HUBENÝ, J., BIAČKOVÁ, N., SCHLEZINGEROVÁ, N., NOVÁK, T., MOHR, P., KLÍROVÁ, M. High-frequency neurostimulation of the right inferior parietal cortex alters the sense of agency: Results from tACS/tRNS and rTMS-EEG studies. Neuroimage. 2025, 318("Article Number 121364"), 1-12. ISSN 1053-8119. DOI: 10.1016/j.neuroimage.2025.121364.
- ŠTROBL, J., VIKTORIN, V., PIORECKY, M., GRISKOVA-BULANOVA, I., HUBENÝ, J., BRUNOVSKÝ, M., PÁLENÍČEK, T., KOUDELKA, V. Unveiling stimulus transduction artifacts in auditory steady-state response experiments: Characterization, risks, and mitigation strategies. Biomedical Signal Processing and Control. 2025, 101("Article Number 107128"), 1-14. ISSN 1746-8094. DOI: 10.1016/j.bspc.2024.107128.
- MOHR, P., KOPEČEK, M., BRUNOVSKÝ, M., PÁLENÍČEK, T. Klinická psychofarmakologie. 2. aktualiz. vyd Praha: Maxdorf, 2025. 678 s. Jessenius. ISBN: 978-80-7345-817-1.
- PREISS, M., FŇAŠKOVÁ, M., NEČASOVÁ, M., DOUBKOVÁ, N., WOLFRAMOVÁ, N., SVOBODA, V., ULČÁK, D., SANDERS, E., REKTOR, I. Travelers between cultures: The war and post-war generations. Cambridge Prisms: Global Mental Health. 2025, 12("e137"), 1-8. ISSN 2054-4251. DOI: 10.1017/gmh.2025.10085.
- PREISS, M., DOUBKOVÁ, N., HEISSLER, R., HUTKA, V., LEFEUVRE, I., ROUBALOVÁ KOSTLÁNOVÁ, V., UHMANNOVÁ, M. Ve vyhnanství: Transgenerační vnímání akce Asanace. Preiss, M., Doubková, N., Heissler, R., ed. Vydání první Praha: Academia, 2025. 413 s. neuvedeno. ISBN: 978-80-200-3637-7.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Public Mental Health Research Programme (VP3)

Head: **Karolína Kucharíková**

Profile: The programme focuses on population mental health, psychiatric epidemiology, and evaluation of the effectiveness and economics of health and social services. Specific areas include mental health awareness, prevention and research into stigma and suicide, the mental health of children, adolescents and sexual minorities, and addictive behaviour. Its work primarily involves research and implementation programmes aimed at developing the mental health care system.


Activities in 2025

In 2025, significant findings were published documenting the impact of mental illness on health, social and economic outcomes for individuals and society. Published studies provided new insights into the associations between inflammatory rheumatic and psychiatric diseases, supporting the hypothesis that inflammatory mechanisms play a significant role in the onset and course of mental disorders (Formánek et al.). Further findings documented the mental health of patients with rheumatoid arthritis and axial spondyloarthritis (Husáková et al.), and excess mortality among people hospitalised for alcohol-related disorders before and during the COVID-19 pandemic (Kážmér et al.).

Other publications in leading international journals offered new insights into stigma affecting people with mental illness and its consequences (Kågström et al., eClinicalMedicine), implementation of mental health policies and strategic plans in the WHO European Region (Guerrero et al., Cambridge Prisms: Global Mental Health), and the state of mental health in Central and Eastern Europe (Winkler et al., Lancet Regional Health). In health promotion and prevention, articles mapped trends in alcohol use (Csémy et al.) and cigarette smoking among Czech adolescents (Kážmér et al.), both in the Central European Journal of Public Health, using data from the international HBSC study.

Major implementation activities included PREPO – Prevention and Promotion of Mental Health in the Adult Population of the Czech Republic, and Gradient – Effective Support for People with Personality Disorders in the Czech Republic. PREPO focused on mental health literacy, reducing stigma, developing preventive interventions and supporting the quality of life of people with mental illness or at risk of developing it. Gradient aimed to improve access to and quality of care for people with symptoms of borderline personality disorder by implementing approaches based on dialectical behaviour therapy (DBT), training professionals and developing regional service networks. Both projects contributed significantly to community care, professional skills and implementation of evidence-based practices in the Czech mental health care system.

Research projects also examined co-occurring inflammatory rheumatic diseases and the health and economic impact of early dementia diagnosis. Excellent research into digital technologies and well-being continued within DigiWELL. Training in the Všech pět pohromadě programme and other courses supporting the mental health of children and adolescents were also delivered. Training took place under Bez obav as well, a project focusing on parenting skills and anxiety prevention.



Annual Report 2025

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Public Mental Health Research Programme (VP3)


The main international implementation projects focused on population mental health, evidence-based preventive approaches, development of mental health services and improved quality of life for vulnerable groups. The programme implemented Joint Action addressing Dementia and HEALTH (JADE HEALTH), which applies established European approaches to mental health and dementia care. HARMONY, promoting mental health and preventing psychological difficulties in the workplace, also continued.

A major activity was Joint Action on Implementation of Best Practices in the Area of Mental Health (ImpleMENTAL), focusing on suicide prevention and implementation-science findings in this area. It covered suicide prevention strategies and recommended practices through international cooperation (Krishnamoorthy et al.). Activities supporting people with mental illness, tackling stigma and strengthening mental health care systems in the Czech Republic and Europe also continued. EU-PROMENS, an international education project developing the skills of mental health professionals across Europe, played a significant role.

REACHMIND supported the mental health of refugee, migrant and minority children. Promoting Mental Health Literacy among Ukrainian War Refugees in Czechia and Beyond supported mental health literacy among war refugees from Ukraine. National Consultancy to Strengthen MHPSS Capacity for Labor Offices, Integration Centers and MoEYS Professionals in Czechia brought together advisory support for labour offices, integration centres and the Ministry of Education, Youth and Sports working with Ukrainian and Czech youth in the Czech Republic.

Key results in 2025


- FORMÁNEK, T., MLADÁ, K., MOHR, P., LIM, MF., OLEJAROVA, M., PAVELKA, K., WINKLER, P., OSIMO, EF., JONES, PB., HUSAKOVA, M. Psychiatric morbidity in people with autoimmune arthritides as a model of inflammatory mechanisms in mental disorders. BMJ Mental Health. 2025, 28(1), "Article Number e301506". ISSN 2755-9734. DOI: 10.1136/bmjment-2024-301506. IF 4.900.
- GUERRERO, Z., KÅGSTRÖM, A., TOMÁŠKOVÁ, H., ALIEV, A., YON, Y., LAZERI, L., REDLICH, C., WINKLER, P. Implementation of mental health policies and plans across the WHO European region: Barriers and facilitators. Cambridge Prisms: Global Mental Health. 2025, 12(e121), 1-8. ISSN 2054-4251. DOI: 10.1017/gmh.2025.10070. IF 3.400.
- KÁŽMÉR, L., ŠÍBA, O., ORLÍKOVÁ, B. Excess mortality in people hospitalised for alcohol use disorders before and during the pandemic - A registry-based retrospective cohort study. Drug and Alcohol Review. 2025, 44(4), 1229-1239. ISSN 0959-5236. DOI: 10.1111/dar.14045. IF 2.600.



Public Mental Health Research Programme (VP3)

- KÅGSTRÖM, A., GUERRERO, Z., ALIEV, AA., TOMÁŠKOVÁ, H., RUSCH, N., OUALI, U., THORNICROFT, G., SARTORIUS, N., WINKLER, P. Mental health stigma and its consequences: a systematic scoping review of pathways to discrimination and adverse outcomes. eClinicalMedicine. 2025, 89(103588), 1-12. ISSN 2589-5370. DOI: 10.1016/j.eclinm.2025.103588. IF 10.000.
- KRISHNAMOORTHY, S., ARMSTRONG, G., ROSS, V., REIFELS, L., PURDON, H., FRANCIS, J., HAWGOOD, J., MATHIEU, S., KASAL, A., CRAWFORD, A., GUSTAVSON, AM., SZEKELY, A., BARAN, A., ERLANGSEN, A., NEMIRO, A., CURNOW, Ch., REIDENBERG, D., BIECHOWSKA, D., ARENSMAN, E., QUARSHIE, EN., SHAND, F., RAMIREZ, CM., ZBUKVIC, I., GULLESTRUP, J., MCGILL, K. Towards development of guidelines for harnessing implementation science for suicide prevention: an international Delphi expert consensus study. BMJ public health. 2025, 3(1), "e001206". ISSN 2753-4294. DOI: 10.1136/bmjph-2024-001206.
- WINKLER, P., GUERRERO, Z., KÅGSTRÖM, A., PETRÁŠOVÁ, M., PASHOJA, AC., QIRJAKO, G., HRISTAKEVA, V., GERMANOV, D., KUZMAN, MR., KUHARIĆ, DB., HAVLÍKOVÁ, L., EEK, H., MARON, E., ŐR, D., WERNIGG, R., FANAJ, N., KRASNIQI, E., SILE, L., BRINKMANE, K., LEVICKAITĖ, K., GRIGAITĖ, U., MANUSHEVA, N., KALPAK, G., IVANOVIC, I., CHIHAI, J., MIHAELA, B., GONDEK, TM., TODZIA-KORNAŚ, A., MIHAI, A., MOLNAR, R. Mental health in Central and Eastern Europe: a comprehensive analysis. Lancet Regional Health-Europe. 2025, 57(101464), 1-17. ISSN 2666-7762. DOI: 10.1016/j.lanepe.2025.101464. IF 13.000.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Sleep and Chronobiology Research Centre (C1)

Head: **Jana Kopřivová**

Profile: The centre conducts preclinical research (animal modelling) and clinical research into sleep, circadian rhythms and their disorders. It develops and tests non-pharmacological treatments for sleep disorders and approaches to improving cognitive performance, including psychological, electrophysiological and sensory methods and stimuli, and contributes to the development of devices for light therapy.


Activities in 2025

In 2025, preclinical and clinical research examined sleep, circadian rhythms and their disorders, with particular emphasis on testing non-pharmacological interventions. Published findings addressed the effects of bright light on circadian and brain activity in adolescents, regulation of circadian and neuroimmune responses through the STAT3 signalling pathway, and neurobiological mechanisms of autism spectrum disorders studied in animal models. Findings were also published on bio-inspired models of brain networks and their use in artificial intelligence. A major output was the specialist monograph Sleep Medicine in Practice. Data analysis and preparation of further publications also continued, particularly on sleep disorders, sleep EEG analysis and the effects of sleep deprivation.

Clinical research continued two grant-funded projects on insomnia. Intensive data collection was under way in a project evaluating the effectiveness of a home intervention using acoustic stimulation. In a newer project assessing the effect of a psychotherapeutic treatment, pilot measurements were performed, experimental paradigms were established and data collection began. Analyses of existing datasets continued in other projects, for example those on the evaluation of arousal and long-term sleep patterns in the population. Preclinical research continued to examine neurobiological mechanisms regulating behaviour, cognition and stress responses, develop devices for laboratory light stimulation, investigate new therapeutic approaches to neuropsychiatric and neurodegenerative diseases, and develop new activators of the mTOR signalling pathway as add-on medications for treatment-resistant depression.

In 2025, three newly awarded projects began: development of a simulated surgical-stress model, development of new substances to treat schizophrenia and alcohol dependence, and cooperation with industry through a technology-transfer voucher to develop an ultrasound sensing system.

Supervision of university students' degree and qualification theses was also an important part of the centre's work.




Sleep and Chronobiology Research Centre (C1)

Key results in 2025

- BUŠKOVÁ, J. Spánková medicína pro praxi. 1. vyd. Praha: Maxdorf, 2025. 345 s. „neuveden". ISBN: 978-80-7345-829-4.
- FILIPOVSKÁ, E., SKÁLOVÁ, K., SPIŠSKÁ, V., MENDOZA, J., BENDOVÁ, Z. Stat3 Silencing Affects Circadian Clock Gene Expression and Lipopolysaccharide Response in the Suprachiasmatic Nucleus, Cortex, and Glioblastoma Cell Cultures. The FASEB Journal. 2025, 39(10), "Article number e70577". ISSN 0892-6638. DOI: 10.1096/fj.202403177RR.
- KOPŘIVOVÁ, J., KAŇKOVÁ, Z., VLČEK, P., PIORECKÝ, M., MAIEROVA, L., BENDOVÁ, Z., SKÁLOVÁ, K., NEKOVÁŘOVÁ, T. Bright light exposure reduces negative affect and modulates EEG activity in sleep-deprived and well-rested adolescents. Frontiers in Behavioral Neuroscience. 2025, 19(1673093), 1-11. ISSN 1662-5153. DOI: 10.3389/fnbeh.2025.1673093.
- RAMME, A., ZACHOW, M., HABELT, B., VOJTĚCHOVÁ, I., PETRÁSEK, T., WALTEREIT, R., BERNHARDT, N. Behavioral phenotyping identifies autism-like repetitive stereotypies in a Tsc2 haploinsufficient rat model. Behavioral and Brain Functions. 2025, 21("Article number: 20"), 1-16. ISSN 1744-9081. DOI: 10.1186/s12993-025-00284-z.
- VALLVERDU, J., FEINSTEIN, X., ROBERTSON, P., KIPELKIN, I., TALANOV, M. A Bio-realistic Synthetic Hippocampus for Robotic Cognition. BioNanoScience. 2025, 15(4), "Article Number 591". ISSN 2191-1630. DOI: 10.1007/s12668-025-02229-2.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Psychedelic Research Centre (C2)

Head: **Tomáš Páleníček**

Profile: Preclinical and clinical research into psychedelics, spanning molecular studies, analytical methods, tissue-culture experiments, animal behavioural experiments and neuroimaging through to clinical trials with a clear therapeutic focus. Preclinical experiments place strong emphasis on the translational validity of data. Expertise in psychedelics and new synthetic substances.

Activities in 2025

In 2025, members of the Psychedelic Research Centre worked on numerous preclinical and clinical projects examining both the mechanisms of action of psychedelics and new psychoactive substances (NPS), and their therapeutic potential. The clinical study Psilocybin versus ketamine – fast-acting antidepressant strategies in treatment-resistant depression (NU21-04-00307) continued. Patient recruitment was completed, and the study is now in the long-term follow-up phase for treated patients. Unblinding for the primary outcome is expected in July 2026.

Extensive NPS testing continued within the MVČR-NSD project using a randomised crossover design with EEG recording and behavioural analysis, including dozens of additional acute experiments in rats. Results from experiments conducted in previous years were published, involving THC, HHC, MXP, 25E-NBOH, baeocystin and other substances.

In preclinical research, we further developed the GAČR project EEG/ECoG based functional connectivity neuroimaging in the rat. We developed scripts with high translational validity to analyse rat EEG data using methods analogous to those used in humans, particularly through implementation and validation of source-localisation methods. EEG microstate projects also made significant progress: we published the first animal study characterising EEG microstates, while a human study of eyes-closed microstates after psilocybin administration has been submitted to a journal with an impact factor. We are also finalising translational publications comparing the effects of psilocin/psilocybin on eyes-open microstates in rats and humans. Other major publications analyse changes in visual perception after psilocybin in humans and rats, its effects on time perception in healthy volunteers, and the effects of psychedelics on neuroplasticity in primary neuronal cultures. A study replicating the influence of cingulate cortex thickness on psilocybin effects was published. We also contributed to publications on psilocybin treatment for depression and the effects of 5-MeO-DMT on the deconstruction of human consciousness. Several review articles on psychedelics were published as well.


Publications being finalised or under review examine psilocybin's effects on brain-activity complexity using fMRI and EEG data, and the effects of psilocybin and music on brain connectivity in the fMRI psilocybin study. A publication assessing psilocybin's effects on emotional processing of music is also under review. The laboratory continues developing new methods, including behavioural phenotyping through deep learning and AI. Within the international LEAD Agency project, it validates translational animal-EEG methods using forward and gel models to assess how brain-tissue anisotropy affects EEG signal propagation, develops new EEG source-localisation methods, and develops a flexible, biocompatible, 3D-printed silicone implant for animal EEG recording. The centre also secured the prestigious COST Action PSY-NET networking project on psychedelics, with Dr Páleníček serving as Chair.

Psychedelic Research Centre (C2)

The centre also helped prepare three further Horizon projects, which advanced to the second evaluation round. As part of public engagement on science and psychedelic-assisted treatment, the film "Doktor na tripu" premiered in 2025, with members of our team as its main protagonists. It received awards at several national and international festivals. Funding came from several key sources: grants provided the largest share, followed by philanthropic funding from the PSYRES endowment fund. IPO funding covered the smallest share of research activities, despite the centre's exceptionally high publication output.

Key results in 2025

- GREGUŠ D, HLINKA J, TYLŠ F, VIKTORIN V, VIKTORINOVÁ M, BRAVERMANOVÁ A, ANDROVIČOVÁ R, ANDRASHKO V, KORČÁK J, NIKOLIČ M, ADÁMEK P, BENEŠ M, PÁLENÍČEK T*, HORÁČEK J. Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study. Psychopharmacology (Berl). 2025 Dec 13. doi: 10.1007/s00213-025-06983-9.
- PIORECKA V, VEJMOLA C, PESKOVA P, PIORECKY M, JIRICEK S, KOUDELKA V, GRISKOVA-BULANOVA I, PALENICEK T*. Microstate in rats' EEG: a proof of concept study. Transl Psychiatry. 2025 Nov 21;15(1):494. doi: 10.1038/s41398-025-03702-y.
- ŠÍCHOVÁ K, MALLARINO B, JANEČKOVÁ L, PALIVEC P, VÁGNEROVÁ M, VEJMOLA Č, NIKOLIČ M, LADISLAVOVÁ L, MAZOCHOVÁ K, RYŠÁNEK P, ŠÍMA M, ŠAFANDA A, HIEP BQ, KOUTROULI IRA, KUCHAŘ M, PÁLENÍČEK T*. Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. Int J Neuropsychopharmacol. 2025 Aug 1;28(8):pyaf041.
- VEJMOLA Č, ŠÍCHOVÁ K, SYROVÁ K, LUCIE JANEČKOVÁ, VLASTIMIL KOUDELKA, MICHAEL TESAŘ, MAREK NIKOLIČ, MICHAELA VIKTORINOVÁ, FILIP TYLŠ, JAKUB KORČÁK, VOJTĚCH VIKTORIN, EDUARD KELEMEN, TEREZA NEKOVÁŘOVÁ, MARTIN BRUNOVSKÝ, JIŘÍ HORÁČEK, MARTIN KUCHAŘ, PÁLENÍČEK T*. Cross-Species Evidence for Psilocin-induced Visual Distortions: Apparent Motion is Perceived by Both Humans and Rats. Biol Psychiatry Glob Open Sci. 2025, 100524.
- VELLA Y, SYROVÁ K, PETRUŠKOVÁ A, KOUTROULI I, KÚTNA V, PALA J, ŠÍCHOVÁ K, NIKOLIČ M, MAZOCH V, JUROK R, KUCHAŘ M, BENDOVÁ Z, PÁLENÍČEK T. Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium. J Psychopharmacol. 2025 Sep;39(9):1023-1030.



Annual Report 2025

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Research Centre for First Episodes of Severe Mental Illness (C3)

Head: **Filip Španiel**


Profile: Clinically oriented research into the early stages of schizophrenia and bipolar disorder, using neuroimaging and other biological markers in prospectively followed patient cohorts. A parallel aim is to develop digital and telemetry solutions in psychiatry to detect relapse and monitor disease progression, enabling early pharmacological and non-pharmacological interventions.

Activities in 2025

In 2025, Centre C3 built on its long-term research into the early stages of severe mental illness, particularly schizophrenia and bipolar disorder, and further developed its unique longitudinal database and biobank of patients with first-episode psychosis (ESO). Its primary aim remained the integration of clinical, neuroimaging, biochemical, immunological, genetic and digital data to model individual disease trajectories more accurately, predict functional outcomes and identify clinically useful biomarkers. A major advance in 2025 was the transition of the existing data infrastructure towards BRAINSCAPE CAD, a platform for computer-aided decision-making and personalised medicine in psychiatry. Extensive datasets from approximately 400 patients and 200 controls were compiled and delivered to test and train analytical components. They include laboratory parameters, demographic data, disease staging and the temporal dynamics of examinations. Building on earlier morphological and multimodal analyses, work continued on modelling schizophrenia subtypes and predicting long-term functional development. Alongside conventional statistical methods, a data normalisation and interpretation layer was developed in 2025, including standardised metrics, quality control and preparation of inputs for automated analytical pipelines. This established a basis for future use of clinical, laboratory and neuroimaging markers in expert systems supporting clinicians' decisions.

The centre's second major focus in 2025 was the development of digital and telemetry solutions for psychiatry. Building on ITAREPS and AKTIBIPO, work shifted towards deeper integration with BRAINSCAPE CAD and preparation of a telemedicine module for continuous data collection in patients' homes. BRAINSCAPE CAD: The platform's computing and database capacity was expanded in 2025. Dedicated high-performance hardware was brought into operation to run analytical models locally and store sensitive ESO data within BRAINSCAPE. This infrastructure enabled testing of locally deployed language models and other computationally demanding tasks.

Automated analyses: An initial working pipeline for automated processing of laboratory and clinical data was developed. It includes quality control, pseudonymisation, normalisation, conversion of selected parameters into standardised indicators, and preparation of structured inputs for higher-level analytical modules. Development also included a knowledge layer representing relationships between variables based on the literature on schizophrenia pathophysiology, to interpret biomarker data and validate model outputs.




Research Centre for First Episodes of Severe Mental Illness (C3)

Telemedicine module: During the year, data flows were specified for ITAREPS, questionnaire scales, Garmin wearables, a dynamic pupillometer and sleep data. Output formats were defined as time series and aggregated metrics, alongside a patient–device identification system, alert-management principles and interfaces to automated pipelines. A mobile-optimised web version of questionnaires, an SMS notification system for patients and the monitoring team, and internal interfaces for anonymised monitoring of patient activity, data quality and device function were developed. Administrative and regulatory preparations also proceeded for an observational study of five digital solutions for schizophrenia. Their potential to predict relapse will be tested in a one-year prospective follow-up of 100 patients.

Research into brain-activity dynamics, neuroinflammation and schizophrenia heterogeneity also continued in 2025. Building on BRADY/VZ2, this work connects longitudinal neuroimaging data from ESO with biochemical, immunological and clinical parameters. The team optimised a computational framework for modelling nonlinear trajectories of resting-state fMRI signals. An analytical pipeline based on complex Principal Component Analysis (cPCA) was developed to extract spatiotemporal characteristics of the BOLD signal in the infraslow frequency band below 0.1 Hz. The framework was implemented in the NUDZ Hydra/HYDRAdb infrastructure, validated with emphasis on reproducibility, and prepared for parallel processing of extensive multimodal datasets. Three main complex components were described: cPC1, primarily in sensorimotor and dorsal cortical regions; cPC2, corresponding to the Default Mode Network; and cPC3, associated with the dorsal attention network. These components provide a new phase-sensitive view of spontaneous brain activity and a potential normative framework for detecting clinical deviations in patients with schizophrenia.

The biochemical database was also expanded to include new neuroinflammatory and neurodegenerative indicators: cytokines IL-6, IL-10, TNF-α and IL-1β; NfL and GFAP proteins measured using Simoa; and haematological indicators of systemic inflammation, including NLR, MLR and SII. In June 2025, a Luminex xMAP INTELLIFLEX multiplex system was installed in NUDZ laboratories. It enables simultaneous measurement of dozens of cytokines, chemokines and other proteins from a single serum sample, strengthening in-house biomarker analysis. Initial integrated analyses demonstrated relationships between cPCA component parameters and peripheral inflammatory markers. Across the full sample, a higher neutrophil-to-lymphocyte ratio (NLR) was associated with lower explained variance in cPC1 and cPC3. Among patients with schizophrenia, the systemic immune-inflammation index (SII) was also associated with lower cPC1 dominance. Conversely, a more favourable immune profile, expressed as a higher lymphocyte-to-CRP ratio, was associated with greater explained variance in cPC3. These findings support the hypothesis that systemic immune dysregulation is reflected in the functional organisation of brain networks in schizophrenia.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Research Centre for First Episodes of Severe Mental Illness (C3)

Key results in 2025

Centre C3's research activities resulted in a strong publication year in 2025: the team contributed to eight papers published or made available online during the year. Topics covered first-episode psychosis, neuroimaging and normative modelling, metabolic and neuroimmune factors in schizophrenia, digital relapse monitoring, and infraslow oscillations linking brain and bodily dynamics.

Major outputs included papers in the American Journal of Psychiatry, Schizophrenia Bulletin and eLife, alongside publications in Brain Research, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Frontiers in Immunology, Neuropsychobiology, and European Archives of Psychiatry and Clinical Neuroscience. Together, they strengthen C3's profile in multimodal biomarkers, prediction of clinical trajectories and digital tools for early relapse detection.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Virtual Reality Research Centre in Mental Health and Neuroscience (C4)

Head: **Iveta Fajnerová**

Profile: Development, research and implementation of virtual reality (VR) and artificial intelligence technologies for the diagnosis, treatment and prevention of mental disorders, and for education and training in professions exposed to high psychological stress. The centre verifies the effectiveness of digital interventions in clinical practice and transfers them into health care, education and other applied settings.

Activities in 2025


In 2025, the VR centre continued developing and implementing virtual reality and artificial intelligence technologies in mental health, psychotherapy, prevention and cognitive training. A significant part of its work involved research and applied projects using VR and AI tools in clinical practice and research.

In exposure therapy, VR applications developed in earlier projects continued to be used and validated, including TAČR Éta TL03000223 – VRETcity, TAČR GAMA TP01010062 – Braintech: OCD House, and TAČR Éta TL01000309 – VReity. The AZV project NU23-04-00402 on virtual reality in the treatment of obsessive-compulsive disorder also continued, testing OCD House with inpatients and outpatients.

A substantial part of the work took place within OP JAK DigiWELL – Excellent Research in Digital Technologies and Well-Being (CZ.02.01.01/00/22_008/0004583). Development and testing continued in 2025 on BreezeTerraVR, a relaxation-breathing application using biofeedback, and FaceTheCrowdVR for exposure therapy for social anxiety. A beta version of TreKog, an online cognitive-training system for older adults, was completed and feasibility studies began. Coremind introduced a new focus on virtual avatars and conversational AI tools supporting mental and sexual health. Initial prototypes of virtual agents using large language models (LLMs) were developed to serve as virtual therapists and peer consultants for specific target groups. Suitable online platforms for their deployment were investigated and pilot testing prepared. Another project in this area examines attitudes towards climate change through VR tools.

The VR centre also contributed to education and training for professions exposed to high psychological stress. Together with the Department of Psychiatry and Medical Psychology of Charles University's Third Faculty of Medicine and NUDZ, VR technologies were used to teach medical students. Cooperation with the Police of the Czech Republic continued on implementing VR tools for training in breaking serious news and developing further research and training projects, including interviewing vulnerable people and using VR simulators in road safety.

The centre also helped implement VR tools in NUDZ therapeutic programmes, collaborated with partners in the Czech Republic and abroad, and expanded the use of digital technologies in education, research and clinical practice.




Virtual Reality Research Centre in Mental Health and Neuroscience (C4)

Research findings were presented at numerous national and international conferences. The centre continued organising specialist workshops on virtual reality and digital technologies in psychotherapy and mental health. Preparation of scientific publications reporting the results of individual projects also continued throughout the year.

Key results in 2025

- FRANCOVÁ, A., JABLONSKÁ KOLMAN, M., LHOTSKÁ, L., HUSÁK, J., FAJNEROVÁ, I. Efficacy of exposure scenario in virtual reality for the treatment of acrophobia: A randomized controlled trial. Journal of Behavior Therapy and Experimental Psychiatry. 2025, 88(102035), 1-12. ISSN 0005-7916. DOI: 10.1016/j.jbtep.2025.102035.
- JANÍKOVÁ, M., ZUZÁNKOVÁ, K., SCHWAMBERGOVÁ, D., MARTINEC NOVÁKOVÁ, L., FRANCOVÁ, A., DARMOVÁ, B., STOPKOVÁ, P., FAJNEROVÁ, I. Expozice ve virtuální realitě obohacená o čichové podněty u obsedantně-kompulzivní poruchy: studie proveditelnosti. Psychiatrie. 2025, 29(1), 5-8. ISSN 1211-7579.
- FAYETTE, D., JURÍČKOVÁ, V., FAJNEROVÁ, I., HORÁČEK, J., KOZÁK, T. The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients. Cancers. 2025, 17(9), "Article Number: 1488". ISSN 2072-6694. DOI: 10.3390/cancers17091488.
- ADAMCOVÁ, K., STOPKOVÁ, P., JABLONSKÁ, M., JAKEŠ, D., DARMOVÁ, B., FAJNEROVÁ, I. Generalizovaná úzkostná porucha a její léčba. Psychiatrie pro praxi. 2025, 26(2), 75-82. ISSN 1213-0508.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Annual Report 2025

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Centre for Sexual Health and Interventions (C5)

Head: **Kateřina Klapilová**


Profile: The Centre for Sexual Health and Interventions conducts leading multidisciplinary research in sexology and brings evidence-based findings and approaches into clinical and forensic practice. It has two divisions: basic sexology research, and applied research and intervention testing. Basic research groups study sexual neuroscience, psychophysiology and cognitive science at basic and preclinical levels to clarify the physiological, brain and cognitive mechanisms of sexual arousal, desire, orgasm, partner and paraphilic preferences, sexual dysfunctions and sexuality in psychiatric patients. Repeated representative surveys of sexual health and behaviour in the Czech population, sexual minorities and marginalised groups provide national reference data in sexology. Applied research focuses on developing, standardising and implementing diagnostic and risk-assessment tools, and testing the effectiveness of treatments and interventions in sexual health and the prevention of sexual offending.

Activities in 2025

Applied research

Ongoing and new projects

• Parafilik – following completion of the project phase in 2023, the programme's sustainability within the Czech health care system was secured. Professionals from Slovakia and China were also trained.
• SEXHELP: National Helpline for Sexual and Gender Health (Ministry of Labour and Social Affairs, 3249532) – we operate a specialist nationwide helpline within the social services system.
• Competence through Avatars in Sexual Health – Kompas (TAČR, TQ23000104) – realistic VR avatars and interactive scenarios are being developed to practise communication with people experiencing gender incongruence or problematic sexual behaviour. Educational modules for health care, social services and prison staff address first contact, history-taking, risk assessment and legal aspects of communication.
• Sociocultural determinants of the impact of circulating representations on the human mind and opportunities for remediation (OP JAK/Ministry of Education, Youth and Sports, CZ.02.01.01/00/23_025/0008715) – we help analyse the effects of media representations and digital environments on mental processes, attitudes and behaviour. Research addresses problematic cybersexuality, disinformation and social polarisation, among other areas, and contributes to approaches strengthening psychological and societal resilience.



Centre for Sexual Health and Interventions (C5)

Basic research

Ongoing and new projects

• Body or behaviour? The role of physical and behavioural indicators of age and sexual maturity in mate choice among people with paedophilia (GAČR, 23-06662S) – using virtual reality and animated avatars, we examine the role of age-typical behaviour in sexual responses and social interactions among people with paedophilic and teleiophilic preferences.
• The effects of gender nonconformity on minority stress and well-being in individuals of different sexual orientations (GAČR, 25-16933S) – the study maps relationships between sexual orientation, gender nonconformity, minority stress and psychological well-being in childhood and adulthood.
• Links between childhood abuse, offence-supportive cognitions and vulnerability to sexually violent behaviour and/or victimisation (GAČR, 25-17884S) – the project aims to clarify relationships between childhood abuse, cognitive distortions and the risk of sexual violence or victimisation.
• A neurobiological model of paraphilia development in male rats, building on the award-winning ESSM project (GAČR, 26-22378S) – research examines links between conditioned sexual preferences, brain activity and epigenetic mechanisms that may affect sexual behaviour.


Projects completed in 2025

• CZECHSEX (GAČR, 21-31490S) – analysis continues of data from a nationally representative survey, which provided new epidemiological data on sexual health in the Czech population after more than ten years.
• Sociosexual deficits in patients with first-episode psychosis and early-stage schizophrenia: effects on disease progression and sexual remediation strategies (AZV, NU21J-04-00024) – the project identified causes of sociosexual deficits in patients with first-episode schizophrenia and contributed to targeted sexual-remediation methods.
• The genetic architecture of sexual violence (MSCA Fellowships CZ, OP JAK, CZ.02.01.01/00/22_010/0003083) – genomic methods were used to investigate genetic factors associated with sexual violence and lay the foundations for further multidisciplinary research.
• A rat model of clitoral pleasure and clitorodynia (ESSM, RG23-05) – the first animal model of clitoral pleasure and clitorodynia was developed, enabling study of their neural mechanisms and possible treatments.

Key results in 2025

- MARTINEC NOVÁKOVÁ, L., KREJČOVÁ, L., BÁRTOVÁ, K., ANDROVIČOVÁ, R., KLAPILOVÁ, K. Formal help-seeking among community-based Czech individuals with sexual interest in minors is associatedwith the perceived urgency of self-identified concerns. Frontiers in Psychology. 2025, 16("Article Number1546102"), 1-16. ISSN 1664-1078. DOI: 10.3389/fpsyg.2025.1546102.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ




Annual Report 2025

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Centre for Sexual Health and Interventions (C5)

- ZAKRESKI, E., JAHNKE, S., ANDROVIČOVÁ, R., BÁRTOVÁ, K., CHRONOS, A., KREJČOVÁ, L., MARTINEC NOVÁKOVÁ, L., KLAPILOVÁ, K. Preoccupied and Fearful-Avoidant Attachment Styles May Mediate the RelationshipBetween Poor Parental Relationship Quality and SexualInterests in Violence. Archives of Sexual Behavior. 2025, 54(7), 2445-2461. ISSN 0004-0002. DOI: 10.1007/s10508-025-03183-6.
- GERME, K., PERSAD, D., PETIT-ROBINSON, J., AMIR, S., PFAUS, JG. Disruptive effects of d-amphetamine on conditioned sexual inhibition in the male rat. Psychopharmacology. 2025, 242(9), 2097-2110. ISSN 0033-3158. DOI: 10.1007/s00213-025-06786-y.
- PFAUS, JG. Orgasms, sexual pleasure, and opioidreward mechanisms. Sexual Medicine Reviews. 2025, 13(3), 381-393. ISSN 2050-0513. DOI: 10.1093/sxmrev/qeaf023.
- PFAUS, JG., GARCÍA-JUÁREZ, M., ORDÓÑEZ, RD., TECAMACHALTZI-SILVARÁN, MB., LUCIO, RA., GONZÁLEZ-FLORES, O. Cellular and molecularmechanisms of action of ovarian steroid hormones. II: Regulation of sexual behavior in female rodents. Neuroscience and Biobehavioral Reviews. 2025, 168("Article number: 105946"), 1-31. ISSN 0149-7634. DOI: 10.1016/j.neubiorev.2024.105946.
- ABDELLAOUI, A., WESSELDIJK, LW., GORDON, SD., SMIT, DJA., ANDROVIČOVÁ, R., MARTIN, NG., ULLEN, F., MOSING, MA., ZIETSCH, BP., VERWEIJ, KJH. Life without sex: Large-scale study linkssexlessness to physical, cognitive, and personality traits, socioecological factors, and DNA. Proceedings of theNational Academy of Sciences of the United States ofAmerica. 2025, 122(38), "e2418257122". ISSN 0027-8424. DOI: 10.1073/pnas.2418257122.

Dr James G. Pfaus, head of the research division, received the ISSWSH Distinguished Service Award for his contribution to women's sexual health, the Sexual Medicine Reviews Best Paper Silver Prize at the ISSM/ESSM congress, and the Best Presentation Prize at the Dr. Eros SHE conference in Hangzhou, China.



Annual Report 2025

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Centre for Advanced Studies of the Brain and Consciousness (C6)

Head: **Jiří Horáček**

Profile: Basic and applied research into consciousness using neuroimaging and electrophysiological methods, sophisticated experiments and advanced analytical approaches. The centre also extends into the social sciences, examining collective and societal phenomena such as the spread of disinformation.

Activities in 2025


In 2025, research continued on weakly electric fish as an experimental model of schizophrenia. A significant methodological paper was published (Chrtková et al., 2025), introducing a method to separate electrical signals during simultaneous electrocommunication between two individuals. This advance enables more precise analysis of individual behaviour and social interactions, and lays the groundwork for detailed assessment of social-behaviour changes in an animal model of schizophrenia.

The centre also made a major contribution to OP JAK BRADY, with our team analysing time series of brain activity after psilocybin administration. Research primarily characterises dynamic changes in brain activity and their relationship to the phenomenology of the psychedelic experience. Six scientific articles in journals with an impact factor were published within this project in 2025.

Data collection also continued in the PSIKET002 clinical study, supported by the Czech Health Research Council (AZV ČR). In 2025, the study became multicentre, with a second research site established at the Masaryk Memorial Cancer Institute in Brno. Expansion to another site is an important step towards increasing recruitment capacity and the generalisability of findings.

The new OP JAK COREmind project also began in 2025, examining the effects of circulating representations on the human mind and society. NUDZ collaborates with the Institute of Psychology and the Institute of Computer Science of the Czech Academy of Sciences, and the University of West Bohemia in Pilsen.

The project addresses a current societal challenge: the growing volume and speed of circulation of material and media representations, and their potential effects on mental processes, individual behaviour and society. COREmind combines analysis of these effects with development and testing of effective remediation approaches. It has three interconnected research objectives. The first examines effects on individuals and identifies the psychological mechanisms and vulnerabilities shaping them. The second investigates wider societal effects in selected areas, including cybersexuality, gender identity, attitudes towards climate change and political polarisation. The third develops and empirically tests remediation programmes to reduce harmful effects on the human mind and behaviour and strengthen individual and societal resilience.




Centre for Advanced Studies of the Brain and Consciousness (C6)

Within OP JAK COREmind, the NUDZ Centre for Advanced Studies of the Brain and Consciousness also helped organise two specialist conferences in 2025 at the intersection of social and medical aspects of mental health. Art and Mental Health 2025 took place on 2–4 October 2025 in Prague and Louny, focusing on the relationship between art, the brain, the mind and mental health. The second conference, The Front Line of Humanity: War from the Perspective of Medicine, Psychology and Law, was organised with Charles University's Third Faculty of Medicine on 22 October 2025 in Prague. It brought together medical, psychological and legal perspectives on armed conflict and its effects on individuals and society.

Key results in 2025

- BENES, M., PALENICEK, T., HORÁČEK, J. What fMRI studies say about the nature of the psychedelic effect: a scoping review. Frontiers in Neuroscience. 2025, 19, 1606798. DOI: 10.3389/fnins.2025.1606798.
- FAYETTE, D., JURÍČKOVÁ, V., FAJNEROVÁ, I., HORÁČEK, J., KOZÁK, T. The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients. Cancers. 2025, 17(9), 1488. DOI: 10.3390/cancers17091488.
- GREGUŠ, D., HLINKA, J., TYLŠ, F., VIKTORÍN, V., VIKTORÍNOVÁ, M., BRAVERMANOVÁ, A., et al. Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study. Psychopharmacology. 2025. DOI: 10.1007/s00213-025-06983-9.
- GRYGAROVÁ, D., HAVLÍK, M., ADÁMEK, P., HORÁČEK, J., JURÍČKOVÁ, V., HLINKA, J., KESNER, L. Beliefs in Misinformation About COVID-19 and the Russian Invasion of Ukraine Are Linked: Evidence From a Nationally Representative Survey Study. JMIR Infodemiology. 2025, 5, e62913. DOI: 10.2196/62913.
- GRYGAROVÁ, D., KOŽENÝ, J., TIŠANSKÁ, L., HAVLÍK, M., HORÁČEK, J. Trust in official information as a key predictor of COVID-19 vaccine acceptance: evidence from a Czech longitudinal survey study. BMC Public Health. 2025, 25(1), 770. DOI: 10.1186/s12889-025-21988-x.
- HAKENOVÁ, K., MIKULECKÁ, A., HOLUBOVÁ, K., CHVOJKOVÁ, M., ŠLAMBEROVÁ, R., JURCOVIČOVÁ, J., et al. A new two-hit animal model for schizophrenia research: Consequences on social behavior. IBRO Neuroscience Reports. 2025, 19, 38–49. DOI: 10.1016/j.ibneur.2025.05.012.
- CHRTKOVÁ, I., KOUDELKA, V., LANGOVÁ, V., HUBENÝ, J., HORKA, P., VALEŠ, K., et al. Unsupervised electric signal separation for linking behavior and electrocommunication in Gnathonemus petersii. Scientific Reports. 2025, 15(1), 33542. DOI: 10.1038/s41598-025-18291-5.
- JAJČAY, L., TOMEČEK, D., ANDROVIČOVÁ, R., FAJNEROVÁ, I., DECHTERENKO, F., RYDLO, J., et al. Deviation From Typical Brain Activity During Naturalistic Stimulation Is Related to Personality Traits. Psychophysiology. 2025, 62(12), e70203. DOI: 10.1111/psyp.70203.


NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Centre for Advanced Studies of the Brain and Consciousness (C6)

- JIŘÍČEK, S., KOUDELKA, V., MANTINI, D., MAREČEK, R., HLINKA, J. Spatial (mis)match between EEG and fMRI signal patterns revealed by spatio-spectral source-space EEG decomposition. Frontiers in Neuroscience. 2025, 19, 1549172. DOI: 10.3389/fnins.2025.1549172.
- KESNER, L., JURÍČKOVÁ, V., GRYGAROVÁ, D., HORÁČEK, J. Impact of Media-Induced Uncertainty on Mental Health: Narrative-Based Perspective. JMIR Mental Health. 2025, 12, e68640. DOI: 10.2196/68640.
- KLUČKOVÁ, T., NIKOLIC, M., TYLŠ, F., VIKTORÍN, V., VEJMOLA, C., VIKTORÍNOVÁ, M., et al. The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting. Pharmacological Reports. 2025, 77(4), 1024–1039. DOI: 10.1007/s43440-025-00742-5.
- RUDOLFOVÁ, V., ANTOSOVÁ, E., PETRÁSEK, T., VALEŠ, K., LANDOVÁ, E., FRYNTA, D., NEKOVÁŘOVÁ, T. Consistency of cognitive performance in spatial navigation and its link to activity and boldness in laboratory rats. Behavioural Processes. 2025, 228, 105205. DOI: 10.1016/j.beproc.2025.105205.
- VEJMOLA, C., SICHOVÁ, K., SYROVÁ, K., JANEČKOVÁ, L., KOUDELKA, V., TESAŘ, M., et al. Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats. Biological Psychiatry Global Open Science. 2025, 5(5), 100524. DOI: 10.1016/j.bpsgos.2025.100524.
- VLČEK, P., HORÁČEK, J., GRUNEROVÁ-LIPPERTOVÁ, M., BRUNOVSKÝ, M. Therapeutic potential of acetyl-DL-leucine and its L-enantiomer in posterior fossa syndrome: Mechanistic insights. Drug Discovery Today. 2025, 30(6), 104389. DOI: 10.1016/j.drudis.2025.104389.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



Annual Report 2025

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Centre for Perinatal Mental Health (C7)

Head: **Antonín Šebela**

Profile: Clinically oriented research into women's mental health during the perinatal period, examining biopsychosocial factors in the development of mental disorders, including the effects of psychotropic medication on child development. Implementation and evaluation of prevention, screening and early-intervention services.

Activities in 2025

Our centre worked with obstetrics and gynaecology departments to implement a screening programme identifying women at risk of mental health difficulties after childbirth. It has now been introduced in 45 maternity hospitals in the Czech Republic, screening approximately 2,200 women each month. A support-coordinator role was also introduced in 15 maternity hospitals. This trained NUDZ staff member follows up with women who request support after screening, assesses their current situation, provides an initial psychosocial intervention and connects them to relevant regional services. We also evaluate this process within OPZ+. The centre received the European Commission's REGIOSTARS 2025 award for this programme. We completed development of MoodPass, an application run by the National Screening Centre at the Institute of Health Information and Statistics (ÚZIS), for which we provide expert oversight. Together with partners from Croatia, Cyprus and Ukraine, we launched MoMental, an international project delivering perinatal mental health training to frontline workers during humanitarian and other crises.

In 2025, three grant-funded applied and implementation research projects were carried out (AZV, OPZ+, Erasmus+).

Key results in 2025

In 2025, the Perinatal project won REGIOSTARS 2025 in the "A Social and Inclusive Europe" category: https://www.dotaceeu.cz/cs/evropske-fondy-v-cr/novinky/cesky-projekt-zvitezil-v-soutezi-regiostars-2025

- ŠEBELA, A., HORÁKOVÁ, A., NĚMCOVÁ, H., KUKLOVÁ, M., NOSKOVÁ, E., ŠVANCER, P., BYATT, N., JANOVSKA, A., HRDLIČKOVÁ, K. Mom Supporting Mom: Effective Peer Support Intervention for Women with Postpartum Psychological Distress. Psychosocial Intervention. 2025, 34(3), 151-160. ISSN 1132-0559. DOI: 10.5093/pi2025a12
- NĚMCOVÁ, H., KUKLOVÁ, M., HRDLIČKOVÁ, K., HORÁKOVÁ, A., ŠEBELA, A. The relationship between maternal psychopathology and maternal-fetal attachment: a cross-sectional study from the Czech Republic. BMC Psychology. 2025, 13("Article number: 248"), 1-10. ISSN 2050-7283. DOI: 10.1186/s40359-024-02308-1.
- NĚMCOVÁ, H., BLASKOVA, T., HORÁKOVÁ, A., KUKLOVÁ, M., HRDLIČKOVÁ, K., ŠEBELA, A. Effects of in vitro fertilization and intracytoplasmic sperm injection treatment on female patients' perinatal mental health: systematic review and meta-analysis. Frontiers in Reproductive Health. 2025, 7("Article Number 1668831"), 1-23. ISSN 2673-3153. DOI: 10.3389/frph.2025.1668831.

Projects undertaken in 2025

Project title	Project ID	Lead recipient	NUDZ investigator
National projects			
Czech Health Research Council (AZV)			
Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression	NU21-04-00307	NUDZ	MUDr. Tomáš Páleníček, Ph.D.
Predicting functional outcome in schizophrenia from multimodal neuroimaging and clinical data	NU21-08-00432	Institute of Computer Science, CAS	MUDr. Filip Španiel, Ph.D.
Concurrence of the rheumatic and psychiatric diseases: epidemiology, identification of the risk-group population and economic costs	NU21-09-00297	Institute of Rheumatology	PhDr. Petr Winkler, Ph.D.
Deficits in the sociosexual functioning of patients with first episodes and early onset schizophrenia: Impact on disease progression and sexological remediation strategies	NU21J-04-00024	NUDZ	Mgr. Renáta Androvičová, Ph.D.
Early-stage identification of schizophrenia subtypes using a multimodal biomarker fingerprints	NU22-04-00143	NUDZ	MUDr. Filip Španiel, Ph.D.
The pathophysiological alterations in the brain after post-psychotic state and perinatal hypoxia	NU22J-04-00061	NUDZ	Mgr. Lenka Kletečková, Ph.D.
Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation(dmPFC-rTMS) in the augmentation of antidepressants (DOPRERA study). Efficacy, tolerability and neurophysiological changes	NU22-04-00192	NUDZ	Doc. MUDr. Martin Bareš, Ph.D.
Disruption of spatiotemporal coordination as an early marker of schizophrenia: A translational study of a role of frontotemporal interaction	NU22-04-00526	Institute of Physiology, CAS	prof. MUDr. Jiří Horáček, Ph.D., FCMA

Virtual Reality Exposure Therapy in Patients with Obsessive-Compulsive Disorder: A randomized controlled trial	NU23-04-00402	NUDZ	MUDr. Pavla Stopková, Ph.D.
Genomics of physiological regulations in bipolar disorder	NU23-04-00534	NUDZ	prof. Martin Alda, MD FRCPC
Closed-loop auditory stimulation to improve sleep in insomnia	NU23-04-00469	NUDZ	PhDr. Jana Kopřivová, Ph.D.
Novel model of schizophrenia based on Gnathonemus petersii species enriched by the electrical communication and social behaviour evaluation	NW24-04-00413	NUDZ	prof. MUDr. Jiří Horáček, Ph.D., FCMA
Decoding the Interplay of Cholinesterase Inhibitors, Energy Metabolism, Cognitive Decline, and Hepatotoxicity: Insights from Animal Models	NW24J-04-00140	University of Hradec Králové	RNDr. David Kolář, Ph.D.
Diarylethylamine derivates methoxphenidine and its potential therapeutic benefit for the therapy of treatment resistant depression	NW24-04-00412	NUDZ	RNDr. Karel Valeš, Ph.D.
Development of novel activators of mTOR signaling pathway as adjunct therapy in treatment-resistant depression	NW24-04-00422	NUDZ	doc. RNDr. Zdeňka Bendová, Ph.D.
Effect of cognitive behavioral therapy for insomnia on emotion regulation	NW24J-04-00083	NUDZ	Mgr. Karolina Janků, Ph.D.
Health and Economic Outcomes of Early Dementia Diagnosis: Understanding the Role of Comorbidities	NW24J-07-00064	NUDZ	Ing. Hana Marie Broulíková, Ph.D.
Neural predictors of therapeutic success of transcranial MAgnetic Stimulation of the brain in obsessive-COmpulsive Disorder (MASCOD)	NW25-04-00023	NUDZ	doc. MUDr. Monika Klírová, Ph.D.

Breaking the code: deciphering electrical communication in Gnathonemus petersii fish in modeling negative symptoms of schizophrenia	NW25-04-00454	NUDZ	prof. MUDr. Jiří Horáček, Ph.D., FCMA
Emotion recognition in schizophrenia spectrum disorders: From predictors to outcomes	NW25J-04-00057	NUDZ	Mgr. Barbora Keřková, Ph.D.
Novel dual action drugs for the treatment of schizophrenia and alcohol addiction	NW25-08-00286	NUDZ	RNDr. Tomáš Petrásek, Ph.D.
Digital phenotyping as a marker of clinical development in major psychiatric disorders	NW25-04-00081	Czech Technical University in Prague	prof. MUDr. Tomáš Hájek, Ph.D.
Chemogenetically Induced Sensory Noise During Adolescence: A Novel Animal Model of Schizophrenia	NW25J-04-00110	Institute of Physiology, CAS	Mgr. Petr Adámek, Ph.D.
Anti-inflammatory properties of neuroactive steroids	NW25J-04-00127	Institute of Endocrinology, Prague	Mgr. Lenka Kletečková, Ph.D.

Czech Science Foundation (GAČR)			
Promoting spatial memories during sleep and by closed-loop targeted memory reactivation	22-16874S	NUDZ	PhDr. Jana Kopřivová, Ph.D.
Olfactory perception and reactivity in individuals with anxious and obsessive-compulsive behavioural traits	22-31662S	NUDZ	Mgr. Lenka Martinec Nováková, Ph.D.
The role of parvalbumin-positive interneurons in a rat model of schizophrenia induced by maternal immune activation	23-06546S	NUDZ	RNDr. Tomáš Petrásek, Ph.D.
Symmetries of brain connectivity	23-07074S	NUDZ	Ing. Mgr. Jaroslav Hlinka, Ph.D.
Body or behavior? Exploring the relative roles of physical versus behavioral indicators of age in mating contexts in pedophiles and teleiophiles	23-06662S	NUDZ	MSc. Kateřina Klapilová, Ph.D.
Alzheimer´s disease and aging: can mTOR inhibitors kill two birds with one drug?	23-05857S	University of Hradec Králové	RNDr. Karel Valeš, Ph.D.
Metabolic and functional effects of 3α5β neuroactic steroids in perinatal brain damage	23-05746S	Institute of Endocrinology, Prague	Mgr. Grygoriy Tsenov, MSc., Ph.D.
EEG/ECoG based functional connectivity neuroimaging in the rat - optimisation, standardisation and translational leapin neuropsycopharmacology	23-07578K	NUDZ	MUDr. Tomáš Páleníček, Ph.D.
Alone: A mixed-methods perspective on loneliness and solitude	24-10889S	NUDZ	prof. MUDr. Pavel Mohr, Ph.D.
Novel cariprazine-derived D2/5-HT3 receptor modulators with potential implications for treating schizophrenia and depressive symptoms	24-11191O	NUDZ	Mgr. Radomír Jůza, Ph.D.
The influence of gender nonconformity on minority stress and well-being in individuals of diverse sexual orientations	25-16933S	NUDZ	Mgr. Klára Bártová, Ph.D. et Ph.D.

How early sexual trauma relates to offense-supportive cognitions and vulnerability to sexual perpetration/victimization in adulthood	25-17884S	NUDZ	Mgr. Kateřina Klapilová, Ph.D.
Underpinning transdiagnostic dimensions and clinical targets of psychopathology: the role of personality and emotions	25-162910	NUDZ	PhDr. Nikola Doubková, Ph.D.

Technology Agency of the Czech Republic (TAČR)			
A unique combination of virtual reality and kinesthetic illusions in rehabilitation	FW06010562	VR Medical, s. r. o.	MUDr. Filip Španiel, Ph.D.
Development of a receptor biochip for the control and regulation of steroid hormones	FW06010206	ESSENCE LINE, s. r. o.	RNDr. Karel Valeš, Ph.D.
New biochip and microfluidic diagnostics of circulating biomarkers and pharmacogens in psychiatric and oncological diseases	FW03010186	ESSENCE LINE, s. r. o.	RNDr. Karel Valeš, Ph.D.
Nature-Like Lighting for Laboratory Animal Facilities	FW09020164	Animalab, s. r. o.	Doc. RNDr. Zdeňka Bendová, Ph.D.
Competencies using Avatars for Sexual Health	TQ23000104	NUDZ	Mgr. Kateřina Klapilová, Ph.D.
A simulated operational stress model validated by testing the anti-stress effects of dietary supplements based on biological response modulators	OZ01020009	Ministry of Defence	PhDr. Jana Kopřivová, Ph.D.

Ministry of Labour and Social Affairs (MPSV)			
Effective support for people with personality disorders in the Czech Republic	CZ.03.02.02/00/ 22_031/0001468	NUDZ	Mgr. Bc. Ondřej Krupčík
Prevention and promotion of mental health of adult population in Czechia 1 (PREPRO 1)	CZ.03.02.02/00/ 22_031/0003822	NUDZ	Mgr. Slavomíra Pukanová
Crisis helpline for sexology	3249532	NUDZ	Mgr. Kateřina Klapilová, Ph.D. / Mgr. Kateřina Potyszová
Free from Fears	CZ.03.03.01/00/ 23_051/0004599	NUDZ	Marie Polášková, MSc.
Early identification and targeted interventions for families at risk of psychosocial stress in the perinatal period: the implementation phase	CZ.03.03.01/00/ 23_051/0004843	NUDZ	MUDr. Antonín Šebela, Ph.D.

Ministry of Education, Youth and Sports (MŠMT)			
Investigating the genetic architecture of sexual violence	CZ.02.01.01/00/ 22_010/0003083	NUDZ	Mgr. Renáta Androvičová, Ph.D.
From Magic to Pharmaceutical Drugs Using Psychoactive Mushrooms	LUAIZ24146	NUDZ	MUDr. Tomáš Páleníček, Ph.D.
The role of gut microbiota in the pathophysiology of schizophrenia	LUAUS25249	NUDZ	MUDr. Filip Španiel, Ph.D.

MŠMT – Operational Programme Johannes Amos Comenius (OP JAK)			
Brain dynamics, OP JAK	CZ.02.01.01/00/ 22_008/0004643	Institute of Computer Science, CAS	prof. MUDr. Jiří Horáček, Ph.D., FCMA
DigiWELL, OP JAK	CZ.02.01.01/00/ 22_008/0004583	University of Ostrava	PhDr. Petr Winkler, Ph.D.
BRAINSCAPE: Cross-sectoral collaboration for the development of new technologies in psychiatry – precision medicine and new therapies, OP JAK	CZ.02.01.01/00/ 23_020/0008560	NUDZ	prof. MUDr. Pavel Mohr, Ph.D.
Social-Cultural Determinants of Circulation of Representations: The Impact on Human Mind and Strategies of Remediation, OP JAK	CZ.02.01.01/00/ 23_025/0008715	NUDZ	prof. MUDr. Jiří Horáček, Ph.D., FCMA

Ministry of the Interior (MV)			
NPS-FORTOX, New psychoactive substances: forensic-toxicology research center	VK01010212	University of Chemistry and Technology, Prague	MUDr. Tomáš Páleníček, Ph.D.
(MEDEVAC) Capacity building in public mental health research and service development in Ukraine	NA	NUDZ	PhDr. Petr Winkler, Ph.D.

International projects and cooperation			
European Commission (EC)			
Revolution of sleep diagnostics and personalized health care based on digital diagnostics and therapeutics with health data integration (SLEEP REVOLUTION)	H2020 965417	HASKOLINN I REYKJAVIK EHF	doc. MUDr. Jitka Bušková, Ph.D.
2PS - Prevent & Protect through support (Prevention of child sexual exploitation)	HE-CL3-2021-FCT-01-11	Polish platform for Homeland Security(Stowarzyszenie Polska Platforma	Mgr. Kateřina Klapilová, Ph.D.
STOP CSAM Scalable Technology for Online Prevention of Child Sexual Abuse and Child Sexual Abuse Materials	101084719	CHARITE - UNIVERSITAETSMEDIZIN BERLIN	Mgr. Kateřina Potyszová / Mgr. Lucie Krejčová, Ph.D.
TRUSTING A TRUSTworthy speech-based AI monitorING system for the prediction of relapse in individuals with schizophrenia	H2020 101080251	ACADEMISCH ZIEKENHUIS GRONINGEN (UMCG)	MUDr. Filip Španiel, Ph.D.
Programme MERIT - Central Bohemia Mobility Programme for Excellence in Research, Innovation and Technology	101081195	SIC – Central Bohemian Innovation Centre	PhDr. Petr Winkler, Ph.D., RNDr. Karel Valeš, Ph.D.
PsyPal: Psilocybin Therapy for Psychological Distress in Palliative Care Patients	H2020 101137378	ACADEMISCH ZIEKENHUIS GRONINGEN	MUDr. Tomáš Páleníček, Ph.D.
EU PROMENS Capacity-building on mental health: multidisciplinary training programme and exchange programme for health professionals	HADEA/2023/ OP/0020	GFA Consulting Group GmbH	PhDr. Petr Winkler, Ph.D.

Joint Action addressing DEmentia and HEALTH	101183247	FUNDESALUD Spain	MUDr. Matěj Kučera
HARMONY – Healthy and resilient mindset with an organized, nurturing, and digital workplace for you	101187046	RIGAS STRADINA UNIVERSITATE	Mgr. Lucie Havlíková
REACHMIND-Refugee, Education, And Children Mental health IN Development: Empowering children, parents and teachers in promoting and protecting refugee, migrant and minority children's mental health	101190350	INTERNATIONAL ORGANIZATION FOR MIGRATION	PhDr. Petr Winkler, Ph.D.
Democratization at stake? Comparing Anti-Gender Politics in CEE and NME countries (Antigender-Politics)	CA23149	University Bochum	PhDr. Pavla Doležalová, Ph.D.
INTEGRATE - Interdisciplinary Network for Training, Education, and Growing Research into Applications of and Therapeutic Expertise around Psychedelics	101226862	ACADEMISCH ZIEKENHUIS GRONINGEN	MUDr. Tomáš Páleníček, Ph.D.
JA PRISM: Prevention oriented RIghts-based approach to Support Mental health in vulnerable population groups	101233316	ASOCIACIÓN INSTITUTO DE INVESTIGACIÓN EN SISTEMAS DE SALUD-BIOSISTEMAK	Mgr. Eva Tušková, Ph.D.
MOMental - Cross-Border Collaboration for Maternal Mental Health in Crisis Settings	KA220-ADU	Roditelji u Akciji, Birth Forward, NGO Ukrainian Midwives' Union	MUDr. Antonín Šebela, Ph.D.


Cost Action: Psychedelic renaissance: turn on, tune in and drop in(PSY-NET)	CA24130	NUDZ	MUDr. Tomáš Páleníček, Ph.D.

WHO/UNICEF			
National Consultancy to Strengthen MHPSS Capacity for Labor Offices, Integration Centers and MoEYS professionals in Czechia	UNICEF	NUDZ	PhDr. Petr Winkler, Ph.D.
WHO – Collaborating Centre	WHO	NUDZ	PhDr. Petr Winkler, Ph.D.

Other R&D support			
The Kooperativa Foundation supports the mental health of mothers and their children	Donation agreement Nk67/2021	NUDZ	MUDr. Antonín Šebela, Ph.D.
Psychedelic Research Endowment Fund: Activities and research on the antidepressant potential of psilocybin and ketamine and the neurobiology of antidepressant effects	Endowment contribution	NUDZ	MUDr. Tomáš Páleníček, Ph.D.
Ultrasound sensing system (Central Bohemian Innovation Centre)	4228235	NUDZ	RNDr. Tomáš Petrásek, Ph.D.
(MEDEVAC) Capacity building in public mental health research and service development in Ukraine	MZ	NUDZ	PhDr. Petr Winkler, Ph.D.
Deep sleep deficit as a correlate of glymphatic dysfunction in psychotic illness (3.LF UK)	270423	NUDZ	MUDr. Radana Měrková
ESSM: A rat model of clitoral pleasure and clitorodynia	RG23-05	NUDZ	Dr. Jim Pfaus
CZECRIN	Cooperation agreement	Faculty of Medicine, Masaryk University, Brno	MUDr. Tomáš Novák, Ph.D.
ILIA study: Randomised controlled multicentre clinical trial of relapse monitoring using smartphones and web applications in patients with schizophrenia or schizoaffective disorder	VSF3_2021-120	Klinikum der Technischen Universitat Munchen	MUDr. Filip Španiel, Ph.D.
VR Drive Sim Pro – Police Edition – proof of concept	n/a	Space s.r.o.	Mgr. et Mgr. Iveta Fajnerová, Ph.D.

Funding providers and project numbers in 2025

Funding provider	Number of projects	NUDZ as lead recipient
Czech Health Research Council (AZV)	19	15
Czech Science Foundation (GAČR)	14	11
Technology Agency of the Czech Republic (TAČR)	6	1
Ministry of Labour and Social Affairs (MPSV)	5	5
Ministry of Education, Youth and Sports (MŠMT)	7	4
Ministry of the Interior (MV)	1	0
European Commission (EC)	15	1
WHO/UNICEF	2	2
Other R&D support	9	8
Total	**78**	**47**




Contract research 2025

Protocol number	Study title	Sponsor/CRO	Principal investigator
1346-0013	A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia	Boehringer Ingelheim International GmbH/ IQVIA RDS CZ	MUDr. Mgr. Barbora Kohútová, Ph.D.
1346-0014	An open label, single arm, extension trial to eXamine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X)	Boehringer Ingelheim International GmbH/ IQVIA RDS CZ	MUDr. Mgr. Barbora Kohútová, Ph.D.
IBA1156	First cholce Antidepressants in - monitoring of GP's prescription habits in the Czech Republic – FIAT	Angelini Pharma / IBA / Mindpax	MUDr. Filip Španiel, Ph.D.
382-201-00001	A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder	Otsuka Pharmaceutica l/CRO Syneos	Doc. MUDr. Martin Bareš, Ph.D.
67953964MDD 3003	VENTURA-LT; Phase 3: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)	Janssen Research & Development, LLC/CRO IQVIA	MUDr. Jiří Renka
NIRVANA-22423	A randomized, parallel-group treatment, Phase 2, double-blind, 2-arm pilot study to investigate the efficacy and safety of elinzanetant capsules compared with placebo capsules for treatment of sleep disturbances associated with menopause. BAY 3427080 / elinzanetant	Bayer, s. r. o.	Doc.MUDr. Jitka Bušková, Ph.D.

Contract research 2025

Protocol number	Study title	Sponsor/CRO	Principal investigator
COMP006	A Phase III, multicentre, randomised, double-blind, controlled study to investigate the efficacy, safety, and tolerability of two initial administrations of COMP360 in participants with treatment-resistant depression	Compass Pathway/CRO ICON	MUDr. Tomáš Páleníček, Ph.D.
BTL-699_CTCZ200	Evaluation of Changes in Brain Reward Pathway Activity after rTMS Therapy via fMRI	BTL Healthcare Technologies a.s.	doc. MUDr. Monika Klírová, Ph.D
NW-3509/023/III/2024	A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability, of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient's current antipsychotic medication(s).	Newron Pharmaceutica ls S.p.A /CRO Clinirx	MUDr. Miloslav Kopeček, Ph.D.



Science and research outputs

The following outputs were produced in 2025, classified by RIV category:

J – Jimp – Article in an impact-factor journal (WoS) – of which Q1 according to WoS	136 69 (51 %)
Jsc, Jost – Article in a journal without an impact factor (Scopus and other databases)	9
B01. Book/monograph	3
C01. Chapter in a scientific monograph	2
G01. Organisation or hosting of a professional event	2

Publications in Q1 impact-factor journals according to WoS in 2025, listed alphabetically by first author. NUDZ authors are highlighted.


ABDELLAOUI, A., WESSELDIJK, LW., GORDON, SD., SMIT, DJA., **ANDROVIČOVÁ, R.**, MARTIN, NG., ULLEN, F., MOSING, MA., ZIETSCH, BP., VERWEIJ, KJH. Life without sex: Large-scale study links sexlessness to physical, cognitive, and personality traits, socioecological factors, and DNA. Proceedings of the National Academy of Sciences of the United States of America. 2025**, 122(38**), "e2418257122". ISSN 0027-8424. DOI: 10.1073/pnas.2418257122. IF 9.100.

BEČEV, O., LASKOV, O., BAKŠTEIN, E., ŠTROBL, J., HUBENÝ, J., BIAČKOVÁ, N., SCHLEZINGEROVÁ, N., NOVÁK, T., MOHR, P., KLÍROVÁ, M. High-frequency neurostimulation of the right inferior parietal cortex alters the sense of agency: Results from tACS/tRNS and rTMS-EEG studies. Neuroimage. 2025, **318**("Article Number 121364"), 1-12. ISSN 1053-8119. DOI: 10.1016/j.neuroimage.2025.121364. IF 4.500.

CONTI, F., LAZZARA, F., THERMOS, K., ZINGALE, E., SPYRIDAKOS, D., ROMANO, GL., DI MARTINO, S., MICALE, V., **KUCHAŘ, M**., SPADARO, A., PIGNATELLO, R., ROSSI, S., D'AMICO, M., PLATANIA, ChBM., DRAGO, F., BUCOLO, C. Retinal pharmacodynamic and pharmacokinetic profile of cannabidiol in an in vivo model of retinal excitotoxicity. European Journal of Pharmacology. 2025**, 991**(177323), 1-14. ISSN 0014-2999. DOI: 10.1016/j.ejphar.2025.177323. IF 4.700.

DALLMER-ZERBE, I., KOPAL, J., **PIDNEBESNA, A.,** CUROT, J., DENUELLE, M., DE BARROS, A., SOL, J., VALTON, L., BARBEAU, E., **HLINKA, J.** Pro-ictal, rather than pre-ictal, brain state marked by global critical slowing and local gamma power increase. Clinical Neurophysiology. 2025, **175**("Article Number 2110742"), 1-13. ISSN 1388-2457. DOI: 10.1016/j.clinph.2025.2110742. IF 3.600.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



DANDA, H., MAZOCHOVÁ, K., ŠÍCHOVÁ, K., MAZOCH, V., OLEJNÍKOVÁ-LADISLAVOVÁ, L., SYROVÁ, K., JURÁSEK, B., CIHLÁŘOVÁ, P., JUROK, R., **PÁLENÍČEK, T**. Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025**, 140**(111439), 1-8. ISSN 0278-5846. DOI: 10.1016/j.pnpbp.2025.111439. IF 3.900.

DESTOOP, M., **MOHR, P.**, BUTLEN, F., KERI, P., SAMOCHOWIEC, J., DE PICKER, L., FIORILLO, A., KUYPERS, KPC., DOM, G. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper. European Psychiatry. 2025, **68(**1), "e3". ISSN 0924-9338. DOI: 10.1192/j.eurpsy.2024.1806. IF 6.700.

DIETZE, LMF., MCWHINNEY, SR., FAVRE, P., ABE, Ch., ALEXANDER, N., BARKHAU, C., BENEDETTI, F., BERK, M., BOEN, E., BOYE, B., BROSCH, K., CANALES-RODRIGUEZ, EJ., CANNON, DM., CARRUTHERS, SP., CORKUM, ELV., DANNLOWSKI, U., DIAZ-ZULUAGA, AM., DOHM, K., ELVSASHAGEN, T., FLINKENFLUEGEL, K., FORTEA, L., FURLONG, LS., GOLDSTEIN, BI., GROTEGERD, D., GRUBER, M., HAARMAN, BCM., HOWELLS, FM., JAHANSHAD, N., JAMALABADI, H., JANSEN, A., **HÁJEK, T**. White matter microstructure in obesity and bipolar disorders: an ENIGMA bipolar disorder working group study in 2186 individuals. Molecular Psychiatry. 2025, **30**(5), 1770-1779. ISSN 1359-4184. DOI: 10.1038/s41380-024-02784-2. IF 10.100.

FABRIK, I., KUPCIK, R., FABRIKOVA, **D., CHVOJKOVÁ, M., HOLUBOVÁ, K., HAKENOVÁ, K**., HORAK, M., SOUKUP, J., MANETHOVA, M., RUSINA, R. Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients. Proteomics. 2025, **25**(15), 42-49. ISSN 1615-9853. DOI: 10.1002/pmic.70006. IF 3.900.

FORMÁNEK, T., MLADÁ, K., MOHR, P., LIM, MF., OLEJAROVA, M., PAVELKA, K.**, WINKLER, P.**, OSIMO, EF., JONES, PB., HUSAKOVA, M. Psychiatric morbidity in people with autoimmune arthritides as a model of inflammatory mechanisms in mental disorders. BMJ Mental Health. 2025, **28**(1), "Article Number e301506". ISSN 2755-9734. DOI: 10.1136/bmjment-2024-301506. IF 4.900.


GHOSH, S., DALLMER-ZERBE, I., REHAK BUCKOVA, B., **HLINKA, J**. Amplitude entropy captures chimera resembling behavior in the altered brain dynamics during seizures. Scientific Reports. 2025, **15**(1), "Article Number 14212". ISSN 2045-2322. DOI: 10.1038/s41598-025-97854-y. IF 3.900.

GOODWIN, GM., AARONSON, ST., ALVAREZ, O., CARHART-HARRIS, R., CHAI-REES, J., CROAL, M., DEBATTISTA, Ch., DUNLOP, BW., FEIFEL, D., HELLERSTEIN, DJ., HUSAIN, MI., KELLY, JR., KIRLIC, N., LICHT, RW., MARWOOD, L., MEYER, TD., MISTRY, S., NOWAKOWSKA, A., **PÁLENÍČEK, T**., REPANTIS, D., SCHOEVERS, RA., SIMMONS, H., SOMERS, M., TEOH, E., TSAI, J., WAHBA, M., WILLIAMS, S., YOUNG, AH., YOUNG, MB., ZISOOK, S., MALIEVSKAIA, E. The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. Journal of Affective Disorders. 2025, **372**(March), 523-532. ISSN 0165-0327. DOI: 10.1016/j.jad.2024.12.061. IF 4.900.

GORE-GORSZEWSKA, G., SEVČÍKOVÁ, A., **BÁRTOVÁ, K., KREJČOVÁ, L., KALENSKÁ, L., ANDROVIČOVÁ, R., WEISS, P., KLAPILOVÁ, K**. Silent struggles: help-seeking barriers for sexual difficulties among adults 50+ in Czechia. Frontiers in Psychology. 2025, **16(**"Article Number: 1622872"), 1-9. ISSN 1664-1078. DOI: 10.3389/fpsyg.2025.1622872. IF 2.900.

GRYGAROVÁ, D., KOŽENÝ, J., TIŠANSKÁ, L., HAVLÍK, M., HORÁČEK, J. Trust in official information as a key predictor of COVID-19 vaccine acceptance: evidence from a Czech longitudinal survey study. BMC Public Health. 2025, **25**("Article number 770"), 1-11. ISSN 1471-2458. DOI: 10.1186/s12889-025-21988-x. IF 3.600.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



CHRTKOVÁ, I., KOUDELKA, V., LANGOVÁ, V., HUBENÝ, J., HORKA, P., **VALEŠ, K.**, CMEJLA, R., **HORÁČEK, J**. Unsupervised electric signal separation for linking behavior and electrocommunication in Gnathonemus petersii. Scientific Reports. 2025, **15**(1), "Article Number 33542". ISSN 2045-2322. DOI: 10.1038/s41598-025-18291-5. IF 3.900.

JANOUSKOVA, M., SEBLOVA, J., KEARNS, PB., **KUČERA, M., KUKLOVÁ, M.,** PEKARA, J., SEBLOVA, D. Navigating dual crises: mental health of Czech health care workers during the Ukrainian refugee influx and COVID-19 pandemic. European Journal of Psychotraumatology. 2025, 16(1), "Article Number 2455247". ISSN 2000-8198. DOI: 10.1080/20008066.2025.2455247. IF 4.100.

JEEVANANDAM, J., TSENOV, G., DANQUAH, MK., RUIZ-MOLENA, D., BOUSSIOS, S., OVSEPIAN, SV. Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence. Molecular Diagnosis and Therapy. 2025, **30**(1), 19-46. ISSN 1177-1062. DOI: 10.1007/s40291-025-00813-6. IF 4.400.

KAWIKOVA, I., ŠPIČKA, V., LAI, JCK., ASKENASE, PW., WEN, L., KEJIK, Z., JAKUBEK, M., **VALEŠ, K., ŠPANIEL, F**. Extracellular vesicles as precision therapeutics for psychiatric conditions: targeting interactions among neuronal, glial, and immune networks. Frontiers in Immunology. 2025, **16**("Article Number: 1454306"), 1-19. ISSN 1664-3224. DOI: 10.3389/fimmu.2025.1454306. IF 5.900.

KESNER, L., JURÍČKOVÁ, V., GRYGAROVÁ, D., HORÁČEK, J. Impact of Media-Induced Uncertainty on Mental Health: Narrative-Based Perspective. JMIR Mental Health. 2025, **12**("Article Number e68640"), 1-20. ISSN 2368-7959. DOI: 10.2196/68640. IF 5.800.

KÅGSTRÖM, A., GUERRERO, Z., ALIEV, AA., TOMÁŠKOVÁ, H., RUSCH, N., OUALI, U., THORNICROFT, G., SARTORIUS, N., **WINKLER, P.** Mental health stigma and its consequences: a systematic scoping review of pathways to discrimination and adverse outcomes. eClinicalMedicine. 2025, **89**(103588), 1-12. ISSN 2589-5370. DOI: 10.1016/j.eclinm.2025.103588. IF 10.000.


KIM, NN., WESSELLS, H., DISANTO, ME., FERRINI, MG., LIN, G., **PFAUS, JG**., PRIVIERO, F., YONG, PJ., PODLASEK, CA. Basic science and translational research: recommendations from the Fifth International Consultation for Sexual Medicine (ICSM 2024). Sexual Medicine Reviews. 2025, **13**(4), 483-512. ISSN 2050-0513. DOI: 10.1093/sxmrev/qeaf032. IF 3.400.

KOPŘIVOVÁ, J., KAŇKOVÁ, Z., VLČEK, P., PIORECKÝ, M., MAIEROVA, L., **BENDOVÁ, Z., SKÁLOVÁ, K., NEKOVÁŘOVÁ, T.** Bright light exposure reduces negative affect and modulates EEG activity in sleep-deprived and well-rested adolescents. Frontiers in Behavioral Neuroscience. 2025, **19**(1673093), 1-11. ISSN 1662-5153. DOI: 10.3389/fnbeh.2025.1673093. IF 2.900.

KOROMINA, M., RAVI, A., PANAGIOTAROPOULOU, G., SCHILDER, BM., HUMPHREY, J., BRAUN, A., BIDGELI, T., CHATZINAKOS, Ch., COOMBES, BJ., KIM, J., LIU, X., TERAO, Ch., O'CONNELL, KS., ADAMS, MJ., ADOLFSSON, R**., ALDA, M**. Fine-mapping genomic loci refines bipolar disorder risk genes. Nature Neuroscience. 2024, **28(**7), 1393-1403. ISSN 1097-6256. DOI: 10.1038/s41593-025-01998-z. IF 20.000.

KOUTROULI, I., MAZOCHOVÁ, K., HORSLEY, RR. The antidepressant potential of (2R,6R)-hydroxynorketamine: A detailed review of pre-clinical findings. European Journal of Pharmacology. 2025, **999**("Article Number 177604"), 1-13. ISSN 0014-2999. DOI: 10.1016/j.ejphar.2025.177604. IF 4.700.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



KUCERA, M., SEBLOVA, D., BOSMANS, ,JE., **BROULÍKOVÁ, HM**., KEARNS, PB. Assessing modifiable risk factors for dementia in the Czech Republic: findings from the Survey of Health, Ageing and Retirement in Europe study. European Journal of Public Health. 2025, **35**(4), 701-707. ISSN 1101-1262. DOI: 10.1093/eurpub/ckaf112. IF 3.900.

KUKRÁL, M., PHAM, D., KOHOUT, J., KOHEK, K., **HAVLÍK, M., GRYGAROVÁ, D**. Near-lossless EEG signal compression using a convolutional autoencoder: Case study for 256-channel binocular rivalry dataset. Computers in Biology and Medicine. 2025, **189**(109888), 1-17. ISSN 0010-4825. DOI: 10.1016/j.compbiomed.2025.109888. IF 6.300.

KUZMAN, MR., NORDENTOFT, M., RABALLO, A., **MOHR, P.**, FIORILLO, A., DOM, G., MIHAJLOVIC, G., JENDRICKO, T., CHUMAKOV, E., BARJAKTAROV, S., CARPINIELLO, B., PATARAK, M., MARTIN, L., DUDEK, D., SAMOCHOWIEC, J., TAUBE, M., COURTET, P., BABIC, D., RACETOVIC, G., CATTHOOR, K., ARANGO, C., MARUTA, N., BASAR, K., VAHIP, S., SZEKERES, G., LIEN, L., POPOVA, A., ZHELEV, R., JAASKELAINEN, E., DELIC, M., CHKONIA, E., CHICHAI, J., TELLES-CORREIA, D., COSMAN, DCM., BEEZHOLD, J., FALKAI, P. Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective. European Psychiatry. 2025, **68**(1), "Article Number e107". ISSN 0924-9338. DOI: 10.1192/j.eurpsy.2025.10072. IF 6.700.

LANDOVÁ, E., POLAK, J., JANOVCOVA, M., STOLHOFEROVA, I., PETERKOVA, S., CHOMIK, A., FRYNTA, D. Imprint of ancestral and modern threats in human mind - experience of fear, disgust, and anger. Frontiers in Psychology. 2025, **15**("Article number 1520224"), 1-16. ISSN 1664-1078. DOI: 10.3389/fpsyg.2024.1520224. IF 2.900.

LEFRERE, A., GODIN, O., JAMAIN, S., DANSOU, Y., SAMALIN, L., **ALDA, M**., AOUIZERATE, B., AUBIN, V., REY, R., CONTU, M., COURTET, P., DUBERTRET, C., HAFFEN, E., JANUEL, D., LEBOYER, M., LLORCA, P., MARLINGE, E., MANCHIA, M., NEILSON, S., OLIÉ, E. Refining Criteria for a Neurodevelopmental Subphenotype of Bipolar Disorders: A FondaMental Advanced Centers of Expertise for Bipolar Disorders Study. Biological Psychiatry. 2025, **97**(8), 806-815. ISSN 0006-3223. DOI: 10.1016/j.biopsych.2024.09.025. IF 9.000.


MARTINEC NOVÁKOVÁ, **L., MILETÍNOVÁ, E., KLIKOVÁ, M., BUŠKOVÁ, J**. Nocturnal exposure to a preferred ambient scent does not affect dream emotionality or post-sleep core affect valence in young adults. Scientific Reports. 2024, **14**(1), "Article Number: 10369". ISSN 2045-2322. DOI: 10.1038/s41598-024-60226-z. IF 3.900.

MARTINEC NOVÁKOVÁ, L., KREJČOVÁ, L., BÁRTOVÁ, K., ANDROVIČOVÁ, R., KLAPILOVÁ, K. Formal help-seeking among community-based Czech individuals with sexual interest in minors is associated with the perceived urgency of self-identified concerns. Frontiers in Psychology. 2025, **16**("Article Number 1546102"), 1-16. ISSN 1664-1078. DOI: 10.3389/fpsyg.2025.1546102. IF 2.900.

NĚMCOVÁ, H., KUKLOVÁ, M., HRDLIČKOVÁ, K., HORÁKOVÁ, A., ŠEBELA, A. The relationship between maternal psychopathology and maternal-fetal attachment: a cross-sectional study from the Czech Republic. BMC Psychology. 2025, **13**("Article number: 248"), 1-10. ISSN 2050-7283. DOI: 10.1186/s40359-024-02308-1. IF 3.000.

O'CONNELL, KS., KOROMINA, M., VAN DER VEEN, T., BOLTZ, T., DAVID, FS., YANG, JMK., LIN, K., WANG, X., COLEMAN, JRI., MITCHELL, BL., MCGROUTHER, CC., RANGAN, AV., LIND, PA., KOCH, E., HARDER, A., PARKER, N., BENDL, J., ADORJAN, K., AGERBO, E., ALBANI, D., ALEMANY, S., ALLIEY-RODRIGUEZ, N., ALS, TD., ANDLAUER, TFM., ANTONIOU, A., ASK, H., BASS, N., BAUER, M., BEINS, EC., BIGDELI, TB., **ALDA, M**. Genomics yields biological and phenotypic insights into bipolar disorder. Nature. 2025, **639**(8056), 968-975. ISSN 0028-0836. DOI: 10.1038/s41586-024-08468-9. IF 48.500.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



OMLOR, W., RABE, F., FUCHS, S., SURBECK, W., CECERE, G., HUANG, G., HOMAN, S., KALLEN, N., GEORGIADIS, F., SPILLER, T., SEIFRITZ, E., WEICKERT, T., BRUGGEMANN, J., WEICKERT, C., POTKIN, S., HASHIMOTO, R., SIM, K., ROOTES-MURDY, K., QUIDE, Y., HOUENOU, J., **TOMEČEK, D., ŠPANIEL, F., ŠKOCH, A**. Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA. American Journal of Psychiatry. 2025, **182**(4), 373-388. ISSN 0002-953X. DOI: 10.1176/appi.ajp.20230806. IF 14.700.

ORTIZ, A., HALABI, R., **ALDA, M.,** BURGOS, A., DESHAW, A., GONZALEZ-TORRES, C., HUSAIN, M., O'DONOVAN, C., TOLEND, M., HINTZE, A., MULSANT, B. Day-to-day variability in sleep and activity predict the onset of a hypomanic episode in patients with bipolar disorder. Journal of Affective Disorders. 2025, **374**(April), 75-83. ISSN 0165-0327. DOI: 10.1016/j.jad.2025.01.026. IF 4.900.

ORTIZ, A., HALABI, R., ALDA, M., DESHAW, A., HUSAIN, MI., NUNES, A., O'DONOVAN, C., PATTERSON, R., MULSANT, BH., HINTZE, A. Day-to-day variability in activity levels detects transitions to depressive symptoms in bipolar disorder earlier than changes in sleep and mood. International Journal of Bipolar Disorders. 2025, **13**(1), 1-12. ISSN 2194-7511. DOI: 10.1186/s40345-025-00379-6. IF 3.500.

PATKOVA, Z., **GRYGAROVÁ, D., ADÁMEK, P.**, TŘEBICKÁ FIALOVÁ, J., HAVLICEK, J., **TŘEBICKÝ, V**. Possible Differences in Visual Attention to Faces in the Context of Mate Choice and Competition. Archives of Sexual Behavior. 2025**, 54(**3), 905-919. ISSN 0004-0002. DOI: 10.1007/s10508-025-03086-6. IF 2.900.

PÁTKOVÁ, Ž., TŘEBICKÝ, V., KOCOUREK, M., **SCHWAMBERGOVÁ, D.**, KLEISNER, K., HAVLÍČEK, J., TŘEBICKÁ FIALOVÁ, J. Visual attention to faces during attractiveness and dominance judgements. Evolutionary Human Sciences. 2025, **7**("Article Number e15"), 1-19. ISSN 2513-843X. DOI: 10.1017/ehs.2025.2. IF 2.300.

PÁV, M., **VANÍČEK, O.**, ZÁVORA, J., PEKARA, J., ZAHRÁDKA-KÖHLEROVÁ, M., PAPEŽOVÁ, S., ANDERS, M. Analysing length of stay disparities in inpatient forensic psychiatric care: a cross-sectional study in Czechia. International Journal of Mental Health Systems. 2025, **19**("Article Number 19"), 1-15. ISSN 1752-4458. DOI: 10.1186/s13033-025-00675-9. IF 3.800.


PFAFFENSELLER, B., **SCHNEIDER, J.**, DE AZEVEDO CARDOSO, T., SIMJANOSKI, M., **ALDA, M.**, KAPCZINSKI, F., **BAKŠTEIN, E.** Self-assessment and rest-activity rhythm monitoring for effective bipolar disorder management: a longitudinal actigraphy study. International Journal of Bipolar Disorders. 2025, **13**("Article Number 34"), 1-10. ISSN 2194-7511. DOI: 10.1186/s40345-025-00401-x. IF 3.500.

PFAUS, JG. Orgasms, sexual pleasure, and opioid reward mechanisms. Sexual Medicine Reviews. 2025, **13**(3), 381-393. ISSN 2050-0513. DOI: 10.1093/sxmrev/qeaf023. IF 3.400.

PFAUS, JG., GARCÍA-JUÁREZ, M., ORDÓÑEZ, RD., TECAMACHALTZI-SILVARÁN, MB., LUCIO, RA., GONZÁLEZ-FLORES, O. Cellular and molecular mechanisms of action of ovarian steroid hormones. II: Regulation of sexual behavior in female rodents. Neuroscience and Biobehavioral Reviews. 2025, **168**("Article number: 105946"), 1-31. ISSN 0149-7634. DOI: 10.1016/j.neubiorev.2024.105946. IF 7.900.

PFAUS, JG., ŠPINKA, M. Not To Be Forgotten: Jaroslav Madlafousek's Important Contributions to Sex Research. Archives of Sexual Behavior. 2025, **54**(2), 3071-3078. ISSN 0004-0002. DOI: 10.1007/s10508-025-03218-y. IF 2.900.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



PFAUS, JG., ZAKRESKI, E., QUINTANA, GR. Yes, Sex and Gender Have Separate Identities!. Archives of Sexual Behavior. 2025, **54**(10), 3883-3886. ISSN 0004-0002. DOI: 10.1007/s10508-025-03164-9. IF 2.900.

PIORECKÁ, V., VEJMOLA, Č., PAČESOVÁ, P., **PIORECKÝ, M., JIŘÍČEK, S., KOUDELKA, V., GRISKOVA-BULANOVA, I., PÁLENÍČEK, T**. Microstate in rats' EEG: a proof of concept study. Translational Psychiatry. 2025, **15**(Article number: 494), 1-10. ISSN 2158-3188. DOI: 10.1038/s41398-025-03702-y. IF 6.200.

PIŠL, V., BUCUR, A., PODINA, IR. Revisiting the Semantic Severity of Anxiety and Depression: Computational Linguistic Study of Normalization and Pathologization. Journal of Medical Internet Research. 2025, **27**("Article Number e73950"), 1-10. ISSN 1439-4456. DOI: 10.2196/73950. IF 6.000.

POTOČÁR, L., KOZAK, M., BOE, T., VON SOEST, T. The social gradients in mental health and psychosocial well-being from adolescence to midlife and the mediating role of parenting practices: a national cohort study. Social Science & Medicine. 2025, **383**(118405), 1-11. ISSN 0277-9536. DOI: 10.1016/j.socscimed.2025.118405. IF 5.000.

RAMME, A., ZACHOW, M., HABELT, B., **VOJTĚCHOVÁ, I., PETRÁSEK, T**., WALTEREIT, R., BERNHARDT, N. Behavioral phenotyping identifies autism-like repetitive stereotypies in a Tsc2 haploinsufficient rat model. Behavioral and Brain Functions. 2025, **21**("Article number: 20"), 1-16. ISSN 1744-9081. DOI: 10.1186/s12993-025-00284-z. IF 3.300.

ROBERTS, T., ESPONDA, GM., **KRUPCHANKA, D.**, SHIDHAYE, R., PATEL, V., RATHOD, S. Factors associated with health service utilisation for common mental disorders: a systematic review. BMC Psychiatry. 2018, **18**(262), 1-19. ISSN 1471-244X. DOI: 10.1186/s12888-018-1837-1. IF 2.666.

SAFAROVA, N., **KOLENIČ, M., ŠPANIEL, F**. Beyond dopamine: Exploring anti-inflammatory mechanisms of antipsychotics. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025, **141**("Article Number 111459"), 1-16. ISSN 0278-5846. DOI: 10.1016/j.pnpbp.2025.111459. IF 3.900.


SCOTT, K., KHAYACHI, A., **ALDA, M.**, NUNES, A. Prediction of Treatment Outcome in Bipolar Disorder: When Can We Expect Clinical Relevance?. Biological Psychiatry. 2025, **98**(4), 285-292. ISSN 0006-3223. DOI: 10.1016/j.biopsych.2025.02.005. IF 9.000.

SEIFERT, M., **ŠEBELA, A.**, OLDE, HT. Perceptions, approaches, and needs of Czech GPs in the management of patients with persistent somatic symptoms: the results of a nationwide cross-sectional survey. BMC Primary Care. 2025, **26**("Article number 79"), 1-11. ISSN 2731-4553. DOI: 10.1186/s12875-025-02768-3. IF 2.600.

SEILLIER, L., ČECHOVÁ, B., **SEILLIER, A**., ŠLAMBEROVÁ, R. Psilocybin has a narrow therapeutic window as an antidepressant treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025, **138**("Article Number: 111368"), 1-12. ISSN 0278-5846. DOI: 10.1016/j.pnpbp.2025.111368. IF 3.900.

SFORZA, M., MORIN, ChM., DANG-VU, TT., POMARES, FB., PERRAULT, AA., GOUIN, J., BUSKOVA, J., **JANKŮ, K**., VGONTZAS, A., FERNANDEZ-MENDOZA, J., BASTIEN, CH., RIEMANN, D., BAGLIONI, Ch., CAROLLO, G., CASONI, F., ZUCCONI, M., CASTRONOVO, V., GALBIATI, A., FERINI-STRAMBI, L. Cognitive-behavioural therapy for insomnia mechanism of action: Exploring the homeostatic K-complex involvement. Journal of Sleep Research. 2025, **34**(4), "e14452". ISSN 0962-1105. DOI: 10.1111/jsr.14452. IF 3.900.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



SHAREW, NT., CLARK, SR., PAPIOL, S., HEILBRONNER, U., DEGENHARDT, F., FULLERTON, JM., HOU, L., SHEKHTMAN, T., ADLI, M., AKULA, N., AKIYAMA, K., ARDAU, R., ARIAS, B., HASLER, R., RICHARD-LEPOURIEL, H., PERROUD, N., BACKLUND, L., BHATTACHARJEE, AK., BELLIVIER, F., BENABARRE, A., BENGESSER, S., BIERNACKA, JM., BIRNER, A., MARIE-CLAIRE, C., CERVANTES, P., CHEN, H., CHILLOTTI, C., CICHON, S., CRUCEANU, C., CZERSKI, PM., **NOVÁK, T., STOPKOVÁ, P., ALDA, M.** Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder. Biological Psychiatry: Global Open Science. 2025, **5**(5), 100558. ISSN 2667-1743. DOI: 10.1016/j.bpsgos.2025.100558. IF 3.700.

SHARMA, O., NAYAK, R., MIZRAHI, L., RIKE, WA., CHOUDHARY, A., SADIS, H., HUSSEIN, Y., ROSH, I., TRIPATHI, U., SHEMEN, A., STERN, Y., SQUASSINA, A., **ALDA, M.**, STERN, S. Detecting suicide risk in bipolar disorder patients from lymphoblastoid cell lines genetic signatures. Translational Psychiatry. 2025, **15**("Article Number 339"), 1-17. ISSN 2158-3188. DOI: 10.1038/s41398-025-03573-3. IF 6.200.

SINGH, S., KHAYACHI, A., STERN, S., TRAPPENBERG, T., **ALDA, M.,** NUNES, A. The effects of bipolar disorder granule cell hyperexcitability and lithium therapy on pattern separation in a computational model of the dentate gyrus. Translational Psychiatry. 2025, **15**(Article number: 385), 1-10. ISSN 2158-3188. DOI: 10.1038/s41398-025-03559-1. IF 6.200.


SOLMI, M., THOMPSON, T., CORTESE, S., ESTRADE, A., AGORASTOS, A., RADUA, J., DRAGIOTI, E., VANCAMPFORT, D., THYGESEN, LC., ASCHAUER, H., SCHLOEGELHOFER, M., ASCHAUER, E., SCHNEEBERGER, A., HUBER, ChG., HASLER, G., CONUS, P., DO CUENOD, KQ., VON KANEL, R., ARRONDO, G., FUSAR-POLI, P., GORWOOD, P., LLORCA, P., KREBS, M., SCANFERLA, E., KISHIMOTO, T., RABBANI, G., SKONIECZNA-ZYDECKA, K., BRAMBILLA, P., FAVARO, A., TAKAMIYA, A., **MANKOVÁ, D., ANDRLÍKOVÁ, E., JANKŮ, K.** Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network analyses. European Neuropsychopharmacology. 2025, **90**(January), 1-15. ISSN 0924-977X. DOI: 10.1016/j.euroneuro.2024.07.010. IF 6.700.

ŠTEFKOVÁ-MAZOCHOVÁ, K., DANDA, H., MAZOCH, V., OLEJNÍKOVÁ-LADISLAVOVÁ, L., ŠÍCHOVÁ, K., PASKANOVA, N., VAGNEROVA, M., JURASEK, B., RYSANEK, P., SIMA, M., SAFANDA, A., BUI, QH., **KUCHAŘ, M., PÁLENÍČEK, T**. The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025, **137(**111285), 1-10. ISSN 0278-5846. DOI: 10.1016/j.pnpbp.2025.111285. IF 3.900.

TAP, SC., THOMAS, K., **PÁLENÍČEK, T.,** STENBAEK, DS., OLIVEIRA-MAIA, AJ., VAN DALFSEN, J., SCHOEVERS, R. Concomitant use of antidepressants and classic psychedelics: A scoping review. Journal of Psychopharmacology. 2025, **39**(10), 1072-1088. ISSN 0269-8811. DOI: 10.1177/02698811251368360. IF 5.500.

TIMMERMANN, Ch., SANDERS, JW., REYDELLET, D., BARBA, T., LUAN, LX., SOTO ANGONA, Ó., ONA, G., ALLOCCA, G., SMITH, CH., DAILY, ZG., MASON, NL., KLOFT-HELLER, L., KUCHAŘ, M., JANECKOVA, L., **PÁLENÍČEK, T.**, ERRITZOE, D., RAMAEKERS, JG., CARHART-HARRIS, RL., VEDØY UTHAUG, M. Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness. Neuroscience of Consciousness. 2025, **2025**(1), "niaf007". ISSN 2057-2107. DOI: 10.1093/nc/niaf007. IF 4.300.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ



VAN DER VEERE, PJ., **BROULÍKOVÁ, HM**., HOOGLAND, J., VAN MAURIK, IS., VAN DE GIESSEN, E., VAN HARTEN, AC., BOSMANS, JE., BERKHOF, J., VAN DER FLIER, WM. Long-term cost-effectiveness of a more accurate diagnostic work-up for dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2025, **17**(4), "e70210". ISSN 2352-8729. DOI: 10.1002/dad2.70210. IF 4.400.

VAN OPSTAL, DPJ., KIA, SM., **JAKOB, L.,** SOMERS, M., SOMMER, IEC., WINTER-VAN ROSSUM, I., KAHN, RS., CAHN, W., SCHNACK, HG. Psychosis Prognosis Predictor: A continuous and uncertainty-aware prediction of treatment outcome in first-episode psychosis. Acta Psychiatrica Scandinavica. 2025, **151**(3), 280-292. ISSN 0001-690X. DOI: 10.1111/acps.13754. IF 5.000.

VEJMOLA, Č., ŠÍCHOVÁ, K., SYROVÁ, K., JANEČKOVÁ, L., KOUDELKA, V., TESAŘ, M., NIKOLIČ, M., VIKTORINOVÁ, M., **TYLŠ, F., KORČÁK, J., VIKTORIN, V., KELEMEN, E., NEKOVÁŘOVÁ, T., BRUNOVSKÝ, M., HORÁČEK, J., KUCHAŘ, M., PÁLENÍČEK, T.** Cross-Species Evidence for Psilocin-induced Visual Distortions: Apparent Motion is Perceived by Both Humans and Rats. Biological Psychiatry: Global Open Science. 2025, **5**(5), "Article Number 100524". ISSN 2667-1743. DOI: 10.1016/j.bpsgos.2025.100524. IF 3.700.

VELLA, Y., SYROVÁ, K., PETRUŠKOVÁ, A., KOUTROULI, I., KÚTNA, V., PALA, J., ŠÍCHOVÁ, K., NIKOLIČ, M., MAZOCH, V., JUROK, R., KUCHAŘ, M., **BENDOVÁ, Z., PÁLENÍČEK, T.** Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium. Journal of Psychopharmacology. 2025, **39**(9), 1023-1030. ISSN 0269-8811. DOI: 10.1177/02698811251338232. IF 5.500.

VERDOUX, H., BITTNER, RA., HASAN, A., QUBAD, M., WAGNER, E., LEPETIT, A., ARROJO-ROMERO, M., BACHMANN, Ch., BEEX-OOSTERHUIS, M., BOGERS, J., CELOFIGA, A., COHEN, D., DE BERARDIS, D., DE HERT, M., DE LAS CUEVAS, C., EBDRUP, BH., FOUNTOULAKIS, KN., GUINART, D., KEATING, D., **KOPEČEK, M.,** LALLY, J., LAZARY, J., LUYKX, JJ., AMIGO, OM., MOLDEN, E., NIELSEN, J., O'DONOGHUE, B., OSWALD, P., RADULESCU, FS., ROHDE, Ch. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force. European Psychiatry. 2025, **68**(1), "e17". ISSN 0924-9338. DOI: 10.1192/j.eurpsy.2024.1816. IF 6.700.

VLČEK, P., HORÁČEK, J., GRÜNEROVÁ-LIPPERTOVÁ, M., **BRUNOVSKÝ, M**. Therapeutic potential of acetyl-DL-leucine and its L-enantiomer in posterior fossa syndrome: Mechanistic insights. Drug Discovery Today. 2025, **30**(6), "Article Number 104389". ISSN 1359-6446. DOI: 10.1016/j.drudis.2025.104389. IF 7.500.

NÁRODNÍ ÚSTAV DUŠEVNÍHO ZDRAVÍ

Public engagement 2025

Art – A Journey to the Soul: concert series

In 2025, six classical music concerts were held as part of the Art – A Journey to the Soul series. Featuring outstanding Czech musicians, the concerts were free to attend and organised by the NUDZ Association. Performances took place in the NUDZ foyer and were open to patients, NUDZ staff and external visitors. More at umenicestadoduse.cz.



9th Na hlavu Festival

The ninth Na hlavu Festival was held in cooperation with the Municipal Library of Prague. Its central theme was love. The festival ran from 27 February to 2 March 2025 at the Municipal Library of Prague, offering discussions, lectures and artistic performances. It is led by Dr Karolína Kuchařová, head of the Public Mental Health Research Programme. More at festivalnahlavu.cz.



Mind Laboratory

The Mind Laboratory lecture series takes place every autumn at the Municipal Library of Prague on Mariánské Square. In 2025, topics included sleep, consciousness, borderline personality disorder, modern therapies and depression. Speakers included Prof. Jiří Horáček, Assoc. Prof. Jitka Bušková and Assoc. Prof. Marek Preiss.



Public engagement 2025

Recruitment for the bone marrow donor register

On 28 April, NUDZ held a one-day recruitment event for volunteers wishing to join the bone marrow donor register. It took place at NUDZ from 2 pm to 5 pm, in cooperation with the Czech National Marrow Donor Registry.





Researchers' Night 2025


In 2025, the National Institute of Mental Health joined Researchers' Night for the first time. During this event, academic and research institutions open their doors to the public. Visitors enjoyed lectures, discussions, interactive virtual reality activities, tours of laboratories and other facilities, and the film Doktor na tripu, documenting the Amazon expedition of Dr Tomáš Páleníček and his team. The inaugural event took place on 26 September 2025 from 5 pm and attracted over 200 visitors. Admission was free. More at nocvedcu.cz.











NUDZ Conference 2025

On 6 November 2025, NUDZ held a conference marking the tenth anniversary of the National Institute of Mental Health. Guests included collaborating organisations, partners, representatives of other healthcare institutions, funding agencies and ministries. More at brand.nudz.cz/konference-nudz.











Clinical care



prof. MUDr. Pavel Mohr, Ph.D.
Deputy Director for Clinical Care


The NUDZ Clinic is primarily a specialist psychiatric hospital. It also provides treatment and diagnostic care in neurology, clinical psychology and radiology. Alongside clinical care, it provides teaching and serves as a teaching centre for the Faculty of Medicine (Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague). It contributes to research in other NUDZ programmes and provides undergraduate and specialist training for physicians and psychologists, including a psychiatry residency programme for medical graduates. Its 55 psychiatric beds across three wards are supplemented by six beds in the Sleep Medicine Department, dedicated to specialised polysomnographic examinations.

Inpatient, outpatient and day-hospital services cover a wide range of the most serious mental disorders and directly support ongoing research programmes: psychotic disorders (early psychosis and treatment-resistant schizophrenia), affective disorders (depression and bipolar disorder), anxiety disorders (obsessive-compulsive disorder, panic disorder and agoraphobia, etc.) and sleep disorders.

In addition to acute inpatient care, we provide follow-up care where indicated. Diagnostics use both neuroimaging (magnetic resonance imaging) and electrophysiological methods (electroencephalography and polysomnography), as well as clinical psychology assessments.
Outpatient services cover general psychiatry, geriatric psychiatry, clinical psychology, neurology and rehabilitation. Specialist clinics also provide care for bipolar disorder, early psychosis, affective disorders, sleep disorders and adult ADHD.

The perinatal psychiatry clinic assesses and supports mothers with symptoms of depression and anxiety immediately before and after childbirth. The neuromodulation department treats neuropsychiatric disorders using repetitive magnetic stimulation. The clinic also includes two day hospitals offering specialised therapeutic programmes for anxiety disorders and patients with psychotic disorders.

Organisational structure



Inpatient care

	Wards 1, 2, 3	Sleep Medicine Department	Follow-up Care Department
Total net inpatient reimbursement	82 897 802	8 457 795	4 071 147
Number of inpatient cases	437	796	121
Total case mix	1 080	153,11	
Average reimbursement per inpatient case	**189 697**	**10 625**	**33 646**


Day hospitals

	Number of points	Number of patients
Day Hospital 1	4 593 274	70
Day Hospital 3	5 336 996	46
Total	**9 930 270**	**116**

Outpatient and referred care

Outpatient care	Number of points
Psychiatry Clinic (specialty 305)	9 396 812
Child and Adolescent Psychiatry (specialty 306)	665 943
Clinical Psychology (specialty 901)	4 639 931
Neurology (specialty 209)	7 119 179
Physiotherapy and Occupational Therapy (specialty 902)	5 745 984
Radiology and Imaging – MRI (specialty 809)	2 234 142
Psychiatric Nurse (specialty 914)	89 906
Total	**29 891 897**
of which outpatient care only	17 865 417
of which referred care during hospitalisation	12 026 480

Health insurers' shares of total reimbursements in 2025



Finance and human resources



Ing. Lenka Menoušková
Deputy Director for Finance and Operations

In the 2025 financial year, NUDZ reported a deterioration in its financial results. The organisation recorded a pre-tax loss of CZK 49,932,621.90. Its principal activities generated a loss of CZK 50,059,169.83, while supplementary commercial activities generated a profit of CZK 126,547.93, meeting the statutory requirement for conducting commercial activities.

PRINCIPAL ACTIVITIES

Costs

Personnel costs were the largest expenditure item in the 2025 budget, reaching CZK 355,602,780. Total payroll costs increased by CZK 34 million year on year, including a CZK 27 million rise in salaries. This was primarily due to the general increase in public-sector pay scales from 1 January 2025 under Government Regulation No. 466/2024 Coll. of 18 December 2024. A second factor was the increase in staff numbers as NUDZ joined major projects under operational programmes.

Revenue

Revenue from NUDZ's principal activities increased significantly year on year, by CZK 34 million, or **15%. Transfer revenue,** including grants for scientific research projects, IPO-RVO funding, the founder's operating contribution and grants for residency positions, rose by CZK 34 million.

This reflected an increase in the founder's operating contribution from CZK 10 million to CZK 25 million and NUDZ's participation in projects with larger funding allocations, including international projects.

Other operating revenue increased by approximately CZK 5.2 million year on year, with contract research revenue making a significant contribution.
By contrast, revenue from services fell by approximately CZK 5.7 million, or 4%, in 2025, mainly due to lower clinic revenue.
Although the organisation's revenue grew year on year in 2025, this was insufficient to cover the substantial rise in operating costs.

SUPPLEMENTARY COMMERCIAL ACTIVITIES

Supplementary commercial activities comprise the operation of the NUDZ café and food preparation facility. Following growth in previous years, revenue from these activities fell slightly in 2025. It totalled CZK 3,983 thousand, compared with approximately CZK 4,065 thousand in 2024, a decrease of about 2%. This was probably due to a change in the supplier of staff meals. Costs also rose slightly, and together with lower revenue this reduced the financial result compared with the previous year. Supplementary commercial activities remain profitable and do not place a burden on the organisation's budget.

CASH FLOW AND OPERATING FINANCE

Cash flow developed in line with the plan. At the end of 2025, the organisation received two non-capital operating contributions from its founder, totalling CZK 25.2 million, to supplement funding for its regular activities. These primarily covered salaries, statutory contributions and contributions to the Cultural and Social Needs Fund (FKSP) for administrative and technical staff whose costs were not funded by external grants or health insurer revenue. The founder's operating contributions remain crucial to the organisation.

CONCLUSIONS AND OUTLOOK

The past financial year was challenging for the organisation. Although revenue increased, its growth did not cover rising operating costs, and the organisation ended the year with a loss.

A financial management audit carried out at the end of the year identified several areas requiring greater attention and more efficient financial processes. Its findings confirmed the need for measures to strengthen the organisation's financial stability.

Following the audit, steps were initiated to improve operational efficiency, refine financial management and establish clearer rules for managing the organisation's funds. These measures aim to ensure sustainable operations over the long term and create stable conditions for further development.



Assets and liabilities: balances and movements

Tangible and intangible fixed assets

Accounts 028 and 029 recorded asset disposals of CZK 2,333,737.54 in 2025. Acquisitions mainly comprised IT equipment, PCs and laptops, purchased using grant funds in line with budgets and grant conditions. Accounts 018 and 019 recorded disposals of CZK 63,290.26; licences were acquired. Account 013 (software) recorded disposals of CZK 505,741.28. A financial management information system was acquired.

Inventories

In 2025, routine movements in account 112 changed the linen/footwear balance from CZK 457,115.50 in January to CZK 189,821.77 at year end; cleaning, household and hygiene supplies from CZK 45,491.14 to CZK 41,767.64; maintenance supplies from CZK 413.09 to CZK 555.39; and office supplies from CZK 51,466.67 to CZK 57,477.71. Medical supplies had a balance of CZK 348.12.

Account 132, relating to supplementary activities, had an actual inventory balance of CZK 32,532.73 under method B. This comprises café and food preparation supplies.

Receivables

Account 311 had a balance of CZK 249,384.93 at 31 December 2025. Account 315 (other receivables from principal activities) had a zero balance both in January and at year end. Estimated receivables totalled CZK 17,410,529.62, mainly estimated health insurer revenue at 31 December 2025. The organisation has no overdue receivables, conducts no enforcement or insolvency proceedings, and has neither pursued nor assigned any receivables for collection.

Liabilities

Liabilities to health insurers, social security institutions and employees were settled on **time. Estimated** payables totalled CZK 3,213,893.87, relating to goods received but not yet invoiced, such as medicines, and services including water, sewerage, gas, security, MRI maintenance and catering.

Accruals and deferrals

Accrued expenses (account 383): CZK 493,657.53 at 31 December 2025.
Deferred income (account 384): CZK 351,580.39 at 31 December 2025.
Prepaid expenses (account 381): CZK 1,988,753.56 at 31 December 2025.
Accrued income (account 385): CZK 699,419.79 at 31 December 2025.

Taxes and provisions

The organisation recorded a loss in 2025. No tax arrears were recorded at the 2025 balance sheet date. No provisions for litigation were created, as NUDZ has no litigation that could give rise to liabilities.

Funds

The reserve fund balance at 31 December 2025 was CZK 8,516,633.84.

The asset replacement/investment fund balance at 31 December 2025 was CZK 10,070,141.42.

The Cultural and Social Needs Fund (FKSP) balance at 31 December 2025 was CZK 5,699,727.18.

Balance sheet 2025 (CZK thousand)

No.	Item	Acct.	2025 GROSS	2025 ADJUSTMENTS	2025 NET	2024 PRIOR YEAR
	TOTAL ASSETS		**935 310**	**297 424**	**637 886**	**668 809**
A.	**Fixed assets**		**839 194**	**297 424**	**541 770**	**533 077**
I.	**Intangible fixed assets**		**82 066**	**46 515**	**35 551**	**12 848**
1.	Intangible R&D results	012	3 350	2 428	923	1 317
2.	Software	013	72 101	37 472	34 628	11 531
3.	Intangible rights	014	0	0	0	0
4.	Emission allowances and preferential quotas	015	0	0	0	0
5.	Low-value intangible fixed assets	018	6 615	6 615	0	0
6.	Other intangible fixed assets	019	0	0	0	0
7.	Intangible assets under development	041	0	0	0	0
8.	Advances for intangible fixed assets	051	0	0	0	0
9.	Intangible fixed assets held for sale	035	0	0	0	0

No.	Item	Acct.	2025 GROSS	2025 ADJUSTMENTS	2025 NET	2024 PRIOR YEAR
II.	**Tangible fixed assets**		**757 128**	**250 909**	**506 219**	**520 229**
1.	Land	031	40 776	0	40 776	40 776
2.	Cultural artefacts	032	265	0	265	265
3.	Buildings	021	427 946	54 878	373 069	378 209
4.	Movable assets and sets of movable assets	022	227 989	140 965	87 025	96 200
5.	Permanent crops	025	0	0	0	0
6.	Low-value tangible fixed assets	028	55 067	55 067	0	0
7.	Other tangible fixed assets	029	0	0	0	0
8.	Tangible assets under construction	042	5 085	0	5 085	4 779
9.	Advances for tangible fixed assets	052	0	0	0	0
10.	Tangible fixed assets held for sale	036	0	0	0	0
III.	**Long-term financial assets**		**0**	**0**	**0**	**0**
1.	Equity interests in controlled entities	061	0	0	0	0
2.	Equity interests in associates	062	0	0	0	0
3.	Debt securities held to maturity	063	0	0	0	0
5.	Long-term term deposits	068	0	0	0	0
6.	Other long-term financial assets	069	0	0	0	0
IV.	**Long-term receivables**		**0**	**0**	**0**	**0**
1.	Long-term repayable financial assistance	462	0	0	0	0
2.	Long-term receivables from assigned loans	464	0	0	0	0
3.	Long-term advances paid	465	0	0	0	0
5.	Other long-term receivables	469	0	0	0	0
6.	Long-term transfer advances paid	471	0	0	0	0

No.	Item	Acct.	2025 GROSS	2025 ADJUSTMENTS	2025 NET	2024 PRIOR YEAR
B.	**Current assets**		**96 116**	**0**	**96 116**	**135 732**
I.	**Inventories**		**950**	**0**	**950**	**650**
1.	Materials acquisition	111	0	0	0	0
2.	Materials in stock	112	917	0	917	555
3.	Materials in transit	119	0	0	0	0
4.	Work in progress	121	0	0	0	0
5.	Own-manufactured semi-finished products	122	0	0	0	0
6.	Finished products	123	0	0	0	0
7.	Goods acquisition	131	0	0	0	0
8.	Goods in stock	132	33	0	33	95
9.	Goods in transit	138	0	0	0	0
10.	Other inventories	139	0	0	0	0
II.	**Short-term receivables**		**38 937**	**0**	**38 937**	**45 286**
1.	Trade receivables	311	249	0	249	323
4.	Short-term advances paid	314	1 253	0	1 253	1 295
5.	Other receivables from principal activities	315	0	0	0	0
6.	Short-term repayable financial assistance	316	0	0	0	0
9.	Employee receivables	335	0	0	0	0
10.	Social security	336	0	0	0	0
11.	Health insurance	337	0	0	0	0
12.	Pension savings	338	0	0	0	0
13.	Income tax	341	0	0	0	0
14.	Other taxes, fees and similar charges	342	0	0	0	0
15.	Value added tax	343	0	0	0	0
16.	Receivables from entities outside selected government institutions	344	0	0	0	0
17.	Receivables from selected central government institutions	346	17 336	0	17 336	9 858

No.	Item	Acct.	2025 GROSS	2025 ADJUSTMENTS	2025 NET	2024 PRIOR YEAR
18.	Receivables from selected local government institutions	348	0	0	0	0
28.	Short-term transfer advances paid	373	0	0	0	0
30.	Prepaid expenses	381	1 989	0	1 989	1 109
31.	Accrued income	385	699	0	699	654
32.	Estimated receivables	388	17 411	0	17 411	32 047
33.	Other short-term receivables	377	0	0	0	0
III.	**Short-term financial assets**		**56 229**	**0**	**56 229**	**89 796**
1.	Equity securities held for trading	251	0	0	0	0
2.	Debt securities held for trading	253	0	0	0	0
3.	Other securities	256	0	0	0	0
4.	Short-term term deposits	244	0	0	0	0
5.	Other current accounts	245	10 061	0	10 061	9 522
9.	Current account	241	40 237	0	40 237	72 817
10.	FKSP current account	243	5 819	0	5 819	7 343
15.	Cash equivalents	263	0	0	0	0
16.	Cash in transit	262	0	0	0	0
17.	Cash on hand	261	112	0	112	114

No.	Item	Acct.	CURRENT 2025	PRIOR YEAR 2024
	TOTAL EQUITY AND LIABILITIES		**637 886**	**668 809**
C.	**Equity**		**506 051**	**556 964**
I.	**Entity capital and adjustments**		**568 059**	**567 907**
1.	Entity capital	401	4 072	4 620
3.	Transfers for the acquisition of fixed assets	403	536 626	527 821
4.	Exchange differences	405	0	0
5.	Valuation differences on initial adoption of a method	406	0	0
6.	Other valuation differences	407	0	0
7.	Prior-period corrections	408	27 361	35 466
II.	**Entity funds**		**24 287**	**28 419**
1.	Bonus fund	411	0	0
2.	Cultural and Social Needs Fund	412	5 700	7 380
3.	Reserve fund from improved financial results	413	0	0
4.	Reserve fund from other sources	414	8 517	11 517
5.	Asset replacement/investment fund	416	10 070	9 522
III.	**Financial result**		**-86 294**	**-39 361**
1.	Current-period financial result		-49 933	-39 361
2.	Financial result pending approval	431	0	0
3.	Prior-period financial results	432	-36 361	0
D.	**Liabilities**		**131 835**	**111 845**
I.	**Provisions**		**6 356**	**0**
1.	Provisions	441	6 356	0
II.	**Long-term liabilities**		**219**	**202**
1.	Long-term loans	451	0	0
2.	Long-term repayable financial assistance received	452	0	0
4.	Long-term advances received	455	219	202

No.	Item	Acct.	CURRENT 2025	PRIOR YEAR 2024
7.	Other long-term liabilities	459	0	0
8.	Long-term transfer advances received	472	0	0
III.	**Short-term liabilities**		**125 260**	**111 643**
1.	Short-term loans	281	0	0
4.	Other short-term borrowings	289	0	0
5.	Trade payables	321	0	0
7.	Short-term advances received	324	0	30
9.	Short-term repayable financial assistance received	326	0	0
10.	Employees	331	18 447	17 598
11.	Other employee liabilities	333	68	95
12.	Social security	336	7 061	6 894
13.	Health insurance	337	3 056	2 977
14.	Pension savings	338	0	0
15.	Income tax	341	0	0
16.	Other taxes, fees and similar charges	342	2 388	2 302
17.	Value added tax	343	0	0
18.	Liabilities to entities outside selected government institutions	345	0	0
19.	Liabilities to selected central government institutions	347	0	0
20.	Liabilities to selected local government institutions	349	0	0
32.	Short-term transfer advances received	374	89 804	78 290
35.	Accrued expenses	383	494	115
36.	Deferred income	384	352	16
37.	Estimated payables	389	3 214	2 966
38.	Other short-term liabilities	378	377	360

Income statement 2025 (CZK thousand)

No.	Item	Acct.	2025 Principal activities	2025 Commercial activities	2024 Principal activities	2024 Commercial activities
A.	**TOTAL COSTS**		**446 640**	**3 856**	**402 522**	**3 822**
I.	**Operating costs**		**446 446**	**3 856**	**402 499**	**3 822**
1.	Materials consumed	501	12 224	2 449	11 523	2 389
2.	Energy consumed	502	7 967	199	10 057	281
3.	Other non-stock supplies consumed	503	0	0	0	0
4.	Cost of goods sold	504	0	0	0	0
5.	Capitalisation of fixed assets	506	0	0	0	0
6.	Capitalisation of current assets	507	0	0	0	0
7.	Change in own-produced inventories	508	0	0	0	0
8.	Repairs and maintenance	511	1 509	0	1 026	0
9.	Travel expenses	512	5 817	0	4 299	0
10.	Representation expenses	513	657	0	385	0
11.	Capitalisation of internal services	516	0	0	0	0
12.	Other services	518	29 798	78	28 318	77
13.	Wages and salaries	521	265 637	852	239 016	807
14.	Statutory social insurance	524	85 239	268	77 930	256
15.	Other social insurance	525	1 059	3	969	3
16.	Statutory employee benefit costs	527	2 538	8	2 347	8
17.	Other employee benefit costs	528	0	0	0	0
18.	Road tax	531	0	0	0	0
19.	Property tax	532	29	0	79	0
20.	Other taxes and fees	538	178	0	46	0
22.	Contractual penalties and late-payment interest	541	0	0	0	0


No.	Item	Acct.	2025 Principal activities	2025 Commercial activities	2024 Principal activities	2024 Commercial activities
23.	Other fines and penalties	542	1	0	50	0
24.	Gifts and other gratuitous transfers	543	0	0	0	0
25.	Cost of materials sold	544	0	0	0	0
26.	Inventory shortages and damage	547	11	0	4	1
27.	Allocations to funds	548	0	0	0	0
28.	Depreciation and amortisation of fixed assets	551	22 466	0	22 274	0
29.	Net book value of intangible assets sold	552	0	0	0	0
30.	Net book value of tangible assets sold	553	0	0	0	0
31.	Cost of land sold	554	0	0	0	0
32.	Creation and release of provisions	555	6 356	0	0	0
33.	Creation and release of impairment allowances	556	0	0	0	0
34.	Written-off receivables	557	0	0	0	0
35.	Low-value fixed asset costs	558	2 732	0	2 538	0
36.	Other operating costs	549	2 230	0	1 638	0
II.	**Finance costs**		**194**	**0**	**23**	**0**
1.	Cost of securities and equity interests sold	561	0	0	0	0
2.	Interest	562	0	0	0	0
3.	Exchange losses	563	194	0	23	0
4.	Losses on fair value remeasurement	564	0	0	0	0
5.	Other finance costs	569	0	0	0	0
III.	**Transfer costs**		**0**	**0**	**0**	**0**
1.	Transfer costs of selected central government institutions	571	0	0	0	0
2.	Transfer costs of selected local government institutions	572	0	0	0	0
V.	**Income tax**		**0**	**0**	**0**	**0**
1.	Income tax	591	0	0	0	0
2.	Additional income tax assessments	595	0	0	0	0

No.	Item	Acct.	2025 Principal activities	2025 Commercial activities	2024 Principal activities	2024 Commercial activities
B.	**TOTAL REVENUE**		**396 580**	**3 983**	**362 917**	**4 065**
I.	**Operating revenue**		**128 640**	**3 983**	**129 095**	**4 065**
1.	Revenue from own products	601	0	0	0	0
2.	Revenue from services	602	121 173	3 983	126 868	4 065
3.	Rental revenue	603	0	0	0	0
4.	Revenue from goods sold	604	0	0	0	0
8.	Other revenue from own activities	609	0	0	0	0
9.	Contractual penalties and late-payment interest	641	0	0	0	0
10.	Other fines and penalties	642	0	0	0	0
11.	Revenue from written-off receivables	643	0	0	0	0
12.	Revenue from materials sold	644	0	0	0	0
13.	Revenue from intangible fixed assets sold	645	0	0	0	0
14.	Revenue from tangible fixed assets sold, excluding land	646	0	0	0	0
15.	Revenue from land sold	647	0	0	0	0
16.	Drawdown of funds	648	0	0	0	0
17.	Other operating revenue	649	7 468	0	2 226	0
II.	**Finance income**		**61**	**0**	**44**	**0**
1.	Revenue from securities and equity interests sold	661	0	0	0	0
2.	Interest	662	0	0	0	0
3.	Exchange gains	663	61	0	44	0
4.	Gains on fair value remeasurement	664	0	0	0	0
6.	Other finance income	669	0	0	0	0
IV.	**Transfer revenue**		**267 879**	**0**	**233 779**	**0**
1.	Transfer revenue of selected central government institutions	671	267 879	0	233 779	0
2.	Transfer revenue of selected local government institutions	672	0	0	0	0
C.	**FINANCIAL RESULT**					
1.	Pre-tax financial result	-	-50 059	127	-39 605	243
2.	Current-period financial result	-	-50 059	127	-39 605	243


Institutional and grant funding over the last five years (CZK thousand)

Year	Institutional support (IPO-RVO)	Operating contribution	Other institutional support	Total IF	Grant funding (recognised grants)	Total recognised transfers	Grant share	IF share
2025	**50 553**	**25 191**	**0**	**75 744**	**192 135**	**267 879**	**71,72%**	**28,28%**
2024	50 041	10 000	0	**60 041**	**173 738**	233 779	**74,32%**	**25,68%**
2023	50 041	15 000	0	**65 041**	**191 856**	256 897	**74,68%**	**25,32%**
2022	48 280	25 000	0	**73 280**	**178 634**	251 914	**70,91%**	**29,09%**
2021	49 406	50 000	11 132	**110 538**	**183 012**	293 550	**62,34%**	**37,66%**


NUDZ pre-tax financial results




NUDZ financial performance in detail, before tax



Cost comparison for 2024 and 2025 – principal activities




Revenue comparison for 2024 and 2025 – principal activities




NUDZ financial results 2020–2025 (CZK)


	2020	2021	2022	2023	2024	2025
Material consumption	20 292 486	19 319 986	18 583 873	15 345 018	13 912 391	14 672 262
Of which: medicines	3 993 781	3 272 878	3 995 916	3 981 380	3 175 849	2 863 065
Energy consumption	6 021 458	5 669 159	9 804 332	8 371 997	10 337 764	8 165 710
Services	21 423 848	20 863 263	21 273 493	35 548 104	28 395 353	29 875 978
Personnel costs (excl. contributions)	218 619 508	220 512 303	205 718 729	221 956 932	239 823 016	266 488 443
Depreciation	16 140 842	31 333 034	20 814 938	21 820 388	22 274 231	22 465 545
Other costs	83 256 486	81 657 341	83 288 747	85 182 272	91 601 454	105 964 935
Total costs	365 754 628	379 355 086	359 484 112	388 224 711	406 344 209	450 495 938
Operating revenue	69 659 931	84 251 946	120 493 020	140 664 418	133 159 996	132 623 340
Financial revenue	11 262	1 033	10 358	6 989	44 180	61 467
Transfer revenue	289 610 127	293 551 470	251 915 049	256 898 532	233 778 563	267 878 509
Total revenue	359 281 320	377 804 450	372 418 427	397 569 939	366 982 739	400 563 316
Pre-tax financial result	-6 473 308	-1 550 637	12 934 315	9 345 228	-39 361 470	-49 932 622

Selected total costs in 2024 and 2025







Approved budget for 2026 (CZK)



Financial comparison 2024 and 2025 – total costs



Financial comparison 2024 and 2025 – total revenue



Employees and collaborators (as at 31 December 2025)

483
employees (incl. parental and maternity leave)

338
full-time equivalent employees


307
interns

396
DPČ/DPP

199
research staff

3
staff with disabilities (4 FTE)

70,6 %
women




266 488 443
Salaries incl. other personnel payments (CZK) – total


86 568 630
Employer contributions (CZK) – total

2 464 249
FKSP contributions (CZK) – total


Employee appointments and departures



Employees by age and gender (as at 31 December 2025)




Employees by education (as at 31 December 2025)



Payroll costs over the last five years



Personnel costs (incl. contributions, CZK)



Average salary (CZK) (excl. other personnel payments)

